

Carl Edwards, III, Ph.D.**Conference Activities:**

- Keynote Speaker, IDDDT Meeting, Shanghai, P.R.C, (October 2010);
- Keynote Speaker, Beijing Antibody Conference (November 2010);
- Keynote Speaker, IDDDT Meeting, Shanghai, P.R.C, (October 2009);
- Brendan Society, 5th Biennial Meeting, Carmel Valley Ranch, Carmel CA (March 7-9, 2006);
- International Psoriasis Conference: From Gene to Clinic, December 1-4, 2005, London, England, U.K.;
- American College of Rheumatology Annual Meeting, (2005);
- Conference Organizer: Ernst Schering Research Foundation (ESRF) Foundation Symposium: "Cytokines as Therapeutic Targets" (along with Drs. Khusru Asadullah M.D., Head CRBA Dermatology. Schering AG, Berlin, Germany and Dr. Charles A. Dinarello, M.D., Professor, Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, CO), (November 16-19, 2004);
- Schering AG International Research Meeting (IRM) Poster Presentation Review, (2004);
- Selected Symposium Speaker, Drug Discovery and Development for Inflammatory Diseases, IBC 2nd International Conference, Copenhagen, Denmark, (October 6-7, 2003);
- Selected Symposium Speaker, Scientific Basis of Rheumatology, Royal College of Physicians, London, United Kingdom, (June 24-26, 2002);
- Selected Symposium Speaker, 3rd International Congress of Autoimmunity, Geneva, Switzerland, (February 20-25, 2002);
- Selected Symposium Speaker and Moderator, Macrophage Lineage Cells and Chronic Inflammatory Diseases, Erskine House, Lorne, Victoria, Australia (February 1-3, 2002);
- Selected Symposium Speaker, 11th International Congress of Immunology, Stockholm, Sweden, (July 22-27, 2001);
- Selected Symposium Moderator and Speaker, Pre-EULAR Symposium "Proinflammatory and anti-inflammatory cytokines in the pathogenesis of rheumatoid arthritis: dissection of inflammatory versus bone destructive pathways, Prague, Czechoslovakia, (June 12, 2001);
- Selected Symposium Speaker, 45th Annual Meeting of the Japanese Rheumatism Association, Tokyo, Japan, (May 14-16, 2001);
- Selected Symposium Speaker, Advances in Targeted Therapies Meeting, Nassau, Bahamas, (April 27-May 30, 2001);
- Selected Symposium Speaker, EULAR Satellite Symposium, Nice, France, "The Evolving World of Cytokines in Rheumatoid Arthritis: Novel Treatment Approaches," (June 21-24, 2000);
- Selected Symposium Speaker, Asia and Pacific League of Associations For Rheumatology (APLAR), 9th APLAR Congress of Rheumatology, Beijing, China, (May 21-26, 2000);
- Selected Symposium Speaker, American College of Rheumatology Annual Spring Clinical Meeting, Seattle, WA, "Biology of TNF-Alpha in Health and Disease", (April 14-16, 2000);
- Selected Symposium Speaker, Cytokine and Anti-Cytokine Therapy in Autoimmunity, 2nd International Congress on Autoimmunity, Tel Aviv, Israel, (March 7-12, 1999);
- Selected Symposium Panelist, Biologics in RA Therapy, American College of Rheumatology Annual Meeting, San Diego, CA, (November 8-12, 1998);
- Selected Panelist and Organizer, Anti-TNF- α Therapeutic Strategies. Second Joint Meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research. Jerusalem, Israel, (October 25-30, 1998);
- Selected Panelist, Strategic Research Institute Conference on "TNF Antagonism: A viable Target for Drug Development". February 25-26, 1998. Miami, FL;

- Invited Chair, “Immunopathology of Mucous Membranes and Exocrine Glands”, May 13-16, 1997, Bergen, Norway;
- Invited Symposium Chair, “4th International Congress on the Immune Consequences of Trauma, Shock, & Sepsis”. March 4-8, 1997. Munich, Germany;
- Invited Chair, “IBC Sixth Annual International Symposium on Sepsis, Advances in Treatment and Drug Development”. June 24-26, 1996. Cambridge, MA;
- Invited Co-Chair, “Behavioral Immunology” Symposia, 8th International Congress of Immunology, Budapest, Hungary, (August 18, 1992);
- Selected Panelist, Symposium on Intermittent Inflammatory Disease Processes, Marion Merrell Dow Research Institute, (1990);
- Invited Speaker, University of Illinois Biotechnology Conference, (1989);

Bibliography

(i). Papers in Refereed Journals

1. Gangadharam, P.R.J., **Edwards, III, C.K.**, Murthy, P.S. and P.F. Pratt. 1983. An acute infection model for *Mycobacterium intracellulare* disease using beige mice: Preliminary results. *American Review of Respiratory Diseases*. 127:648-649.
2. Gangadharam, P.R.J. and **Edwards, III, C.K.** 1984. Release of superoxide anion (O₂⁻) from resident and activated mouse peritoneal macrophages infected with *Mycobacterium intracellulare*. *American Review of Respiratory Diseases*. 130:834-838.
3. **Edwards, III, C.K.**, H.B. Hedegaard, A. Zlotnik, P.R.J. Gangadharam, R.B. Johnston, Jr. and M.B. Pabst. 1986. Chronic infection due to *Mycobacterium intracellulare* in mice: association with macrophage release of prostaglandin E₂ and reversal by injection of indomethacin, muramyl dipeptide, or interferon-γ. *Journal of Immunology*. 136:1820-1827.
4. Szeffler, S.J., **Edwards, III, C.K.**, C. Haslett, N.R. Zahniser, J.A Miller and P.F. Henson. 1986. Effect of cell isolation procedures and radioligand selection on the characterization of human leukocyte β-adrenergic receptors. *Biochemical Pharmacology*. 36:1587-1589.
5. Johnston, R.B., S. Kitagawa, **Edwards, III, C.K.**, J.Y. Channon, H. Suzuki, and M.J. Pabst. 1988. The respiratory burst in activated macrophages: studies of its molecular basis and evidence for downregulation in chronic infection. *Advances in Experimental Medicine and Biology*. 239: 63-72.
6. **Edwards, III, C.K.**, J.M. Schepper, L.M. Yungler, and K.W. Kelley. 1988. Somatotropin and prolactin enhance respiratory burst activity of macrophages. *Annals New York Academy of Sciences*. 540: 698-699.
7. **Edwards, III, C.K.**, S.M. Ghiasuddin, J.M. Schepper, L.M. Yungler and K.W. Kelley. 1988. A newly defined property of somatotropin: priming of macrophages for production of superoxide anion. *Science*. 239:769-771.
8. **Edwards, III, C.K.**, M. Jacobs, P. Myers-Keith and L.M. Yungler. 1989. Murine macrophage activation with resorcylic acid lactones (RALs): comparison with diethylstilbestrol and 17β-estradiol. *Immunopharmacology*. 17:107-118.
9. Davila, D.R., **Edwards, III, C.K.**, S. Arkins, J. Simon and K.W. Kelley. 1990. Interferon-γ-induced priming for secretion of superoxide anion and tumor necrosis factor-α declines in macrophages from aged rats. *FASEB Journal*. 4:2906-2911.
10. Dunham, D.M., S. Arkins, **Edwards, III, C.K.**, R. Dantzer and K.W. Kelley. 1990. Role of IFN-γ in counteracting the suppressive effects of TGF-β₂ and glucocorticoids on the production of TNFα; *Journal of Leukocyte Biology*. 48:473-481.
11. Lorrence, R.M., **Edwards, III, C.K.**, R.J. Walter, K.W. Kelley and J.A. Greager. 1990. *In vivo* effects of recombinant interferon-γ: Augmentation of endotoxin-induced necrosis of tumors and priming of macrophages for tumor necrosis factor-α production. *Cancer Letters*. 53:223-229.
12. **Edwards, III, C.K.**, R.M. Lorrence, D.M. Dunham, L.M. Yungler, J.A Greager, R.J. Walter and K.W. Kelley. 1991. Hypophysectomy inhibits the synthesis of tumor necrosis factor-α production by rat

- macrophages: Partial restoration by exogenous growth hormone or interferon. *Endocrinology*. 128:989-996.
13. **Edwards, III, C.K.**, L.M. Yunger, R.M. Lorrence, R. Dantzer and K.W. Kelley. 1991. The pituitary gland is required for protection against the lethal effects of *Salmonella typhimurium*. *Proceedings of the National Academy of Sciences (USA)*. 88:2274-2277.
 14. **Edwards, III, C.K.**, M.J. Myers, K.W., Kelley and L.B. Schook. 1991. Enhanced macrophage antimicrobial activity following dimethylnitrosamine exposure *in vivo* is related to augmented production of reactive oxygen metabolites. *International Journal of Immunopharmacology*. 13:395-411.
 15. **Edwards, III, C.K.**, S.M. Ghiasuddin, A. Blum, L.M. Yunger, R.M. Lorrence and K.W. Kelley. 1992. *In vivo* administration of recombinant growth hormone or interferon- γ activates macrophages: Enhanced resistance to experimental *Salmonella typhimurium* infection is correlated with the generation of reactive oxygen intermediates. *Infection and Immunity*. 60:2514-2521.
 16. Zhou, T., H. Bluethmann, **Edwards, III, C.K.** and J.D. Mountz. 1992. Defective maintenance of T-cell tolerance to a superantigen in MRL-*lpr/lpr* mice. *Journal of Experimental Medicine*. 176:1063-1072.
 17. Mountz, J.D. and **Edwards, III, C.K.** 1992. Murine models of autoimmunity: T cell and B cell defects. *Current Opinions in Rheumatology*. 4:612-620.
 18. Mountz, J.D. and **Edwards, III, C.K.** 1992. Murine models of autoimmunity. *Current Opinions in Rheumatology*. 4:621-629.
 19. **Edwards, III, C.K.**, S. Arkins, L.M. Yunger, A. Blum, R. Dantzer and K.W. Kelley. 1992. The macrophage activating properties of growth hormone. *Cellular and Molecular Neurobiology*. 12:499-510.
 20. Parmely, M.J., W.W. Zhou, **Edwards, III, C.K.**, D.R. Borcharding, R. Silverstein and D.C. Morrison. 1993. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor- α production and protect mice against endotoxin challenge. *Journal of Immunology*. 151:389-396.
 21. Mountz, J.D., T. Zhou, R.E. Long, H. Bluethmann, W.J. Koopman, and **Edwards, III, C.K.** 1994. T-cell influence superantigen-induced arthritis in MRL-*lpr/lpr* mice. *Arthritis and Rheumatism*. 37:113-124.
 22. **Edwards, III, C.K.**, L.M. Watts, M.J. Parmely, M.D. Linnik, R.E. Long and D.R. Borcharding. 1994. The effect of the carbocyclic nucleoside MDL 201,112 on inhibition of interferon- γ -induced priming of Lewis (LEW/N) rat macrophages for enhanced respiratory burst and MHC class II IA antigen expression. *Journal of Leukocyte Biology*. 56:133-149.
 23. Mountz, J.D., T. Zhou, H. Bluethmann, J. Wu and **Edwards, III, C.K.** 1994. Apoptosis defects analyzed in TCR transgenic and *fas* transgenic *lpr* mice. *International Immunology*. 11:321-342.
 24. Bradshaw, M., M. Rutherford, L.B. Schook, D.R. Borcharding, C.D. McWhinney, B.J. Hoepfer and **Edwards, III, C.K.** 1995. Specific transcriptional inhibition of bone marrow-derived macrophage (BMDM ϕ) TNF- α gene expression and protein production using novel enantiomeric carbocyclic nucleoside analogues. *Journal of Pharmacology and Experimental Therapeutics*. 273:1506-1518.
 25. Zhou, T., **Edwards, III, C.K.**, and J.D. Mountz. 1995. Prevention of age-related T cell apoptosis defect in CD2-*fas*-transgenic mice. *Journal of Experimental Medicine*. 182:129-137.
 26. Cullen, C.M., P.F. Bonventre, H. Heeg, H. Bluethmann, J.D. Mountz and **Edwards, III, C.K.** 1995. A *fas* antigen receptor mutation allows development of toxic shock syndrome toxin-1-induced lethal shock in V β 8.2 T-cell receptor transgenic mice. *Pathobiology*. 63:293-304.
 27. Bonventre, P.F., H. Heeg, **Edwards, III, C.K.** and C. Cullen. 1995. A mutation at histidine residue 135 of toxic shock syndrome toxin (TSST-1) yields an immunogenic protein with minimal toxicity. *Infection and Immunity*. 63:509-515.
 28. Mountz, J.D., T.J. Baker, D.R. Borcharding, H. Bluethmann, T. Zhou, and **Edwards, III, C.K.** 1995. Increased susceptibility of *fas* mutant MRL-*lpr/lpr* mice to *Staphylococcal enterotoxin B*-induced Septic Shock. *Journal of Immunology*. 155: 4829-4837.
 29. Borcharding, D.R., B. Butler, S. Mehdi, M.D. Linnik, Mark W. Dudley and **Edwards, III, C.K.** 1996. *Cis*- (1S, 3R)-1-(9-Adenyl)-3-hydroxycyclopentane inhibits the respiratory burst from polymorphonuclear leukocytes and has *in vivo* efficacy in acute and chronic models of inflammation. *Nucleosides & Nucleotides*. 15:967-979.

30. McWhinney, C.D., M. Bradshaw, M. De, D.R. Borcharding, M. Dudley, T.L. Bowlin, N. Peet, L.B. Schook and **Edwards, III, C.K.** 1996. Activation of adenosine A₃ receptors on macrophages inhibits tumor necrosis factor- α . *European Journal of Pharmacology*. 310:209-216.
31. Borcharding, D.R., N.P. Peet, H.R. Munson, H. Zhang, P.F. Hoffman, T.L. Bowlin and **Edwards, III, C.K.** 1996. Carbocyclic nucleosides as inhibitors of human tumor necrosis factor- α production: Effects of the stereoisomers of (3-Hydroxycyclopentyl) adenines. *Journal of Medicinal Chemistry*. 39:2615-2620.
32. Zhou, T., **Edwards, III, C.K.**, P. Yang, Z. Wang, H. Bluethmann, and J.D. Mountz. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in *lpr* mice lacking tumor necrosis factor receptor I. *Journal of Immunology*. 156: 2661-2665.
33. **Edwards, III, C.K.** T. Zhou, J. Zhang, T.J. Baker, M. De, R.E. Long, D.R. Borcharding, T.L. Bowlin, H. Bluethmann, and J.D. Mountz. 1996. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-*lpr/lpr* mice by a transcriptional inhibitor of tumor necrosis factor- α . *Journal of Immunology*. 157:1758-1772.
34. Grom, A.A., K.J. Murray, L. Luyrink, H. Emery, M.H. Passo, D.N. Glass, T. Bowlin, and **Edwards, III, C.K.** 1996. Patterns of expression of tumor necrosis factor- α , tumor necrosis factor- α , and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. *Arthritis and Rheumatism*. 39:1703-1710.
35. Mountz J.D., **Edwards, III, C.K.**, J. Cheng, P. Yang, Z. Wang, C. Liu, X. Su, H. Bluethmann, and T. Zhou. 1996. Autoimmunity due to defective Nur77, *fas*, and TNF-RI apoptosis. *Advances in Experimental Medicine and Biology*. 406: 241-262.
36. Mountz, J.D., T. Zhou, X. Su, J. Cheng, M. Pierson, H. Bluethmann, and **Edwards, III, C.K.** 1996. Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. *Behring Institute Mittring*. 97: 200-219.
37. Solorzano, C.C., J.H. Pruitt, R. Ksontini, P.J. Hess, P.D. Edwards, A. Kaibara, A. Abouhamze, T. Auffenberg, R.E. Galardy, J. N. Vauthey, E.M. Copeland, III, **Edwards, III, C.K.**, G. Y. Lauers, M. Clare-Salzler, S.L.D. MacKay, L.L. Moldawer, and D. D. Lazarus. 1997. Involvement of 26 KD cell-associated TNF- α in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. *Journal of Immunology*. 158:414-419.
38. Haimovitz-Friedman, A., C. Cordon-Cardo, S. Bayoumy, M. McLaughlin, **Edwards, III, C.K.**, E. H. Schuchman, Z. Fuks, and R. Kolesnick. 1997. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. *Journal of Experimental Medicine*. 186:1831-1841.
39. Bowlin, T.L., D.R. Borcharding, **Edwards, III, C.K.**, and C.D. McWhinney. 1997. Adenosine A₃ receptor agonists inhibit murine macrophage tumor necrosis factor alpha production *in vitro* and *in vivo*. *Cellular & Molecular Biology*. 43: 345-349.
40. Su, P. Yang, **Edwards, III, C.K.**, and J.D. Mountz. 1998. Soluble TNF receptor prevents arthritis and pneumonitis in motheaten mice. *Arthritis and Rheumatism*. 41:139-149.
41. Solorzano, C.C., A. Kaibara, P.J. Hess, P.D. Edwards, R. Ksontini, J. Frazier, D. Trujillo, G. Kieft, H. Kohno, M.E. Cosenza, M. Clare-Salzler, S. L.D. MacKay, L.L. Moldawer, and **Edwards, III, C.K.** 1998. Pharmacokinetics, immunogenicity and efficacy of dimeric TNF receptor binding proteins in healthy and bacteremic baboons. *Journal of Applied Physiology*. 84: 1119-1130.
42. Moshyedi, A.K., M.D. Josephs, E.K. Abdalla, S.L.D. MacKay, **Edwards, III, C.K.**, E.M. Copeland, III, and L.L. Moldawer. 1998. Leptin expression is increased in bacterial peritonitis and is under partial regulatory control of tumor necrosis factor- α *Infection and Immunity*. 66: 1800-1802.
43. Ksontini, R., D.B. Colagiovanni, M.D. Josephs, **Edwards, III, C.K.**, C.L. Tannahill, C.C. Solorzano, J. Norman, M. Clare-Salzler, S. L.D. McKay, and L.L. Moldawer. 1998. Disparate roles for TNF- α and *fas* ligand in concanavlin A induced hepatitis. *Journal of Immunology*. 160: 4082-4089.
44. Kuiper, S., L. AB Joosten, A.M. Bendele, **Edwards, III, C.K.**, O.J. Arntz, M. MA Helsen, F. AJ van de Loo, and W.B. van den Berg. 1998. Different roles of tumor necrosis factor- α and interleukin-1 in murine streptococcal cell wall arthritis. *Cytokine*. 10: 690-702.

45. Fleck, M., E.R. Kern, T. Zhou, J. Podlech, W. Wintersberger, **Edwards, III, C.K.**, and J.D. Mountz. 1998. Apoptosis mediated by *fas* but not TNF-Receptor I prevents chronic disease in mice infected with murine *Cytomegalovirus*. *Journal of Clinical Investigation*. 102: 1431-1443.
46. Zhang, H-G, T. Zhou, P. Yang, **Edwards, III, C.K.**, D.T. Curiel, and J.D. Mountz. 1998. Inhibition of Tumor Necrosis Factor- α decreases inflammation and prolongs adenovirus gene expression in lung and liver. *Human Gene Therapy* 9:1875-1884.
47. Al-Humidan, A., **Edwards, III, C.K.**, A. Al-Sofi, M. Dzimiri, S.T. Al-Sedairy and K.S.A. Khabar. 1998. A carbocyclic nucleoside analogue is a TNF-alpha inhibitor with immunosuppressive action: role of prostaglandin E₂ and protein kinase C and comparison with pentoxifylline. *Cellular Immunology*. 188: 12-18.
48. Zhang, H-Ge, X. Su X., W. Liu, P. Yang, P., Z. Wang, Z., **Edwards, III, C.K.**, H. Bluethmann, J. D. Mountz and T. Zhou, T. 1999. Induction of specific T cell tolerance by *fas* ligand-expressing antigen-presenting cells. *Journal of Immunology*. 162: 1423-1430.
49. McComb, J., T Gould, E. Chlipala, R. Senello, J. Frazier, G. Kieft, J. Seely, **Edwards, III, C.K.**, and A.M. Bendele. 1999. Antiarthritic activity of soluble TNF receptor type I form in adjuvant arthritis: correlation of plasma levels with efficacy. *Journal of Rheumatology*. 26:1347-1351.
50. Bendele, A.M., J. McComb, T. Gould, J. Frazier, E. Chlipala, J. Seely, G. Kieft, and **Edwards, III, C.K.** 1999. Combination benefits of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. *Inflammation Research*. 48:453-460.
51. Carney, D.E., C.J. Lutz, A.L. Picone, L.A. Gatto, H.J. Schiller, C.M. Finck, B. Searles, A.M. Paskanik, K. P. Snyder, **Edwards, III, C.K.**, and G.F. Nieman. 1999. Soluble tumor necrosis factor receptor prevents post-pump syndrome. *Journal of Surgical Research*. 83:113-121.
52. Fukuzuka K., J.J. Rosenberg, G.C. Gaines, **Edwards, III, C.K.**, M. Clare-Salzler, S.L. MacKay, L.L. Moldawer, E.M. Copeland, III, and D.W. Mazingo. 1999. Caspase-3-dependent organ apoptosis early after burn injury. *Annals Surgery*. 229: 851-858.
53. Fleck, M., E.R. Kern, **Edwards, III, C.K.**, and J.D. Mountz. 1999. Herpes simplex virus infection induced apoptosis in peritoneal macrophages independent of *fas* and tumor necrosis factor receptor signaling. *Journal of Virology*. 12: 263-275.
54. Torelli, G.F., M.M. Meguid, L.L. Moldawer, **Edwards, III, C.K.**, Kim, H-J, Carter, J.L., Laviano, A., and Fanelli, F.R. 1999. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. *American Journal of Physiology*. 277: R850-R855.
55. **Edwards, III, C.K.** PEGylated recombinant human soluble tumor necrosis factor receptor type I (rHu-sTNF-RI): A novel high-affinity TNF receptor designed for chronic inflammatory diseases. 1999. *Annals of Rheumatic Diseases*. 58: (Suppl I) I73-I81.
56. Bendele, A.M., J. McComb, T. Gould, J. Frazier, E. Chlipala, J. Seely, G. Kieft, and **Edwards, III, C.K.** 1999. Effects of PEGylated soluble tumor necrosis factor receptor Type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats. *Clinical & Experimental Rheumatology*. 17:553-560.
57. Moreland, L.W., D. McCabe, J.R. Caldwell, M. Sach, M. Weisman, G. Henry, J. Seely, S.W. Martin, C. Yee, A.M. Bendele, J. Frazier, T. Kohno, M.E. Cosenza, S. Lyons, J-M. Dayer, A. Cohen and **Edwards, III, C.K.** 2000. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer (TNFbp Dimer) in patients with active refractory rheumatoid arthritis. *Journal of Rheumatology*. 27: 601-609.
58. Fukuzuka, K., **Edwards, III, C.K.**, M. Clare-Salzler, E.M. Copeland, III, L.L. Moldawer, and D.W. Mazingo. 2000. Glucocorticoid-induced, caspase-dependent organ apoptosis early after burn injury. *American Journal Physiology Regulatory Integrative Comparative Physiology*. 278: R1005-R1018.
59. Colagiovanni, D.B., M.A. Suniga, J.L. Frazier, **Edwards, III, C.K.**, M. Fleshner, J.A. McKay, K.L. White, Jr., and G.L. Shopp. 2000. TNF- α blockade by a dimeric TNF type I receptor molecule selectively inhibits adaptive immune responses. *Immunopharmacology & Immunotoxicology*. 22:627-651.
60. Bendele, A.M., E. Chlipala, J. Scherrer, J. Frazier, G. Sennello, W.J., Rich, and **Edwards, III, C.K.** 2000. Combination benefit of treatment with the cytokine inhibitors Interleukin-1 receptor antagonist

- (IL-1ra) and PEGylated Soluble Tumor Necrosis Factor Receptor Type I (sTNF-RI) in animal models of rheumatoid arthritis. *Arthritis and Rheumatism*. 43:2648-2659.
61. Vigers, G.P.A., D.J. Dripps, **Edwards, III, C.K.**, and B.J. Brandhuber. 2000. X-ray crystal structure of a small antagonist peptide bound to the Type - I interleukin-1 receptor. *Journal of Biological Chemistry*. 275:36927-36933.
 62. Davis, M.W., U. Feige, A. M. Bendele, S. Martin, and **Edwards, III, C.K.** 2000. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumor necrosis factor receptor Type I (PEG sTNF-RI): A Clinical Update. *Annals of Rheumatic Diseases (Supplement)*. 59 (Supplement I): i41-i43.
 63. Frishman, J.I., **Edwards, III, C.K.**, M.G. Sonnenberg, T. Kohno, A.M. Cohen, and C.A. Dinarello. 2000. Tumor necrosis factor (TNF)- α -induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors. *The Journal of Infectious Diseases*. 182: 1722-1730.
 64. Zhang, H-G, J. Xie, P. Wang, Y. Wang, L. Xu, D. Liu, H-C Hsu, T. Zhou, **Edwards, III, C.K.**, and J.D. Mountz. 2000. Adeno-associated virus (AAV) production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor- α and reduces arthritis. *Human Gene Therapy*. 11:2431-2442.
 65. Josephs, M.D., F.R. Bahjat, K. Fukuzuka, R. Ksontini, C.C. Solorzano, **Edwards, III, C.K.**, C.L. Tannahill, S.L. MacKay, E.M. Copeland, III, and L.L. Moldawer. 2000. Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF- α and not by Fas ligand. *American Journal of Physiology Regulation Integrated Comparative Physiology*. 278: R1196-R1201.
 66. Nowak, M., G.C. Gaines, J. Rosenberg, R. Minter, F.R. Bahjat, J. Rectenwald, S.L. MacKay, **Edwards, III, C.K.**, and L.L. Moldawer. LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF- α and the TNF-p55 receptor. *American Journal of Physiology Regulation Integrated Comparative Physiology*. 278: R1202-R1209.
 67. Fukuzuka, K., **Edwards, III, C.K.**, M. Clare-Salzer, E.M. Copeland, III, L.L. Moldawer, and D.W. Mazingo. 2000. Glucorticoid and Fas ligand induced mucosal lymphocyte apoptosis after burn injury. *Journal of Trauma*. 49: 710-716.
 68. Davis, M.W., U. Feige, A.M. Bendele, S.W. Martin, and **Edwards, III, C.K.** 2000. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumor necrosis factor receptor type I: a clinical update. *Annals Rheumatic Diseases*. 59 (Supplement 1): i41-43.
 69. Hyka, N., J. -M. Dayer, C. Modoux, T. Kohno, **Edwards, III, C.K.**, P. Roux-Lombard, and D. Burger. Apolipoprotein A-I (ApoAI) inhibits the production of IL-1 β and TNF- α by blocking contact-mediated activation of monocytes by T lymphocytes. 2001. *Blood*. 97: 2381-2389.
 70. Vazquez-Torres, A., G. Fantuzzi, D. Holden, **Edwards, III, C.K.**, C.A. Dinarello, and F.C. Fang. 2001. Defective localization of the NADPH Phagocyte Oxidase to *Salmonella*-containing phagosomes in TNFp55 receptor-deficient macrophages. *Proceedings of the National Academy of Sciences (USA)*. 98: 2561-2565.
 71. **Edwards, III, C.K.** 2001. Combination cytokine therapy in rheumatoid arthritis: The next generation. *Journal of Clinical Rheumatology*. 7:S17-S24.
 72. Dayer, J.M., U. Feige, **Edwards, III, C.K.**, and D. Burger. 2001. Anti-Interleukin-1 therapy in rheumatic diseases. *Current Opinions in Rheumatology*. 13:170-176.
 73. Nicoletti, F., R. DiMarco, I. Conget, R. Gomas, **Edwards, III, C.K.**, K. Bendtzen, and S. Sandler. 2001. Soluble Tumor Necrosis Factor Receptor Type (sTNF-RI) in murine immunoinflammatory diabetes induced by multiple low doses of streptozotocin. *Journal of Autoimmunity*. 15: 395-405.
 74. Hsu, H-C, H-Ge Zhang, G. G. Song, J. Xie, D. Liu, P. Yang, M. Fleck, W. Wintersberger, T. Zhou, **Edwards, III, C.K.**, and J.D. Mountz. 2001. Defective FasL-mediated apoptosis predisposes to development of a post-*Mycoplasma pulmonis*-induced chronic erosive arthritis. *Arthritis and Rheumatism*. 44: 2146-2159.
 75. Rosenberg, J.J., S.W. Martin, G.C. Gaines, K. Fukuzuka, J. Rose, J. Frazier, J. Seely, A. Amicone, W. Boyle, G. Kieft, M.E. Cosenza, T. Kohno, L.L. Moldawer, and **Edwards, III, C.K.** 2001. Development of a novel, non-immunogenic soluble human TNF receptor type I construct that blocks pathological effects of systemic TNF- α in the juvenile *papio*. *Journal of Applied Physiology*. 91: 2213-2223.

76. Oberholzer, A., C. Oberholzer, F.R. Bahjat, **Edwards, III, C.K.**, and L.L. Moldawer. 2001. Genetic determinants of lipopolysaccharide and D-galactosamine-mediated hepatocellular apoptosis and lethality. *Journal of Endotoxin Research*. 7: 375-380
77. Schultz, M.J., A.W. Rijneveld, S. Florquin, **Edwards, III, C.K.**, C.A. Dinarello, and T. van der Poll. 2002. Role of Interleukin 1 in the pulmonary immune response during *Pseudomonas aeruginosa* pneumonia. *American Journal of Physiology-Lung Cellular and Molecular Physiology*. 282:L285-L290.
78. Zacccone, P., Z. Fehervan, L. Blanchard, F. Nicoletti, **Edwards, III, C.K.**, and A. Cooke. Autoimmune thyroid disease induced by thyroglobulin and LPS is inhibited by soluble TNF receptor type I (sTNF-RI). 2002. *European Journal of Immunology*. 32: 1021-1028.
79. Matsuki, Y., L. Li, H-C Hsu, P.A. Yang, R. Zheng, **Edwards, III, C.K.**, I.H. Chaudry, H-G. Zhang and J.D. Mountz. 2002. Soluble Fas gene therapy protects against Fas-mediated apoptosis of hepatocytes but not the lethal effects of Fas-induced TNF- α production by Kupffer cells. 2002. *Cell Death and Differentiation*. 9: 626-635.
80. Rijneveld, A.W., S. Florquin, P. Speelman, **Edwards, III, C.K.**, C.A. Dinarello, and T. van der Poll. 2003. Treatment with recombinant interleukin-1 receptor antagonist only transiently impairs antibacterial defense in murine pneumococcal pneumonia. *Eur. Cytokine Network*. 14:242-245.
81. Lundberg, P., P. Welander, H. Openshaw, C. Nalbandian, **Edwards, III, C.K.**, L. Moldawer, and E. Cantin. 2003. A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation, while an unlinked locus augments resistance of female mice. *J. Virology*. 77:11661-11673.
82. **Edwards, III, C.K.**, S.W. Martin, J. Seely, O. Kinstler, S. Buckel, A.M. Bendele, U. Feige, and T. Kohno. 2003. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. *Advanced Drug Delivery Reviews: Site Specific PEGylation of Polypeptides*. 55:1315-1336.
83. Fathalla, B., K. Hamada, E. Vannier, D. Smith, **Edwards, III, C.K.**, and R. Roubenoff. 2004. Effects of aging and cytokine blockade on inflammatory cachexia. *Clin. Exper. Rheumatology*. 22: 85-90.
84. **Edwards, III, C.K.** 2004. Drug discovery and development for inflammatory diseases: Meeting highlights. *Expert Opin. Ther. Targets*. 8:151-163.
85. Schottelius, A.J.G., L.L. Moldawer, C.A. Dinarello, K. Asadullah, W. Steery, and **Edwards, III, C.K.** 2004. Biology of Tumor Necrosis Factor- α (TNF- α): Implications for psoriasis. *Experimental Dermatology*. 13:193-222.
86. Efron, P.A., H. Tsujimoto, Ungaro, F.R. Bahjat, R. Ungaro, J. Debernardis, C. Tannahill, H.V. Baker, **Edwards, III, C.K.**, and L.L. Moldawer. 2005. Differential maturation of murine bone marrow derived dendritic cells with lipopolysaccharide and tumor necrosis factor- α . *Journal of Endotoxin Research*. 11:145-160.
87. Furst, D., R. Fleischman, E. Kopp, M. Schiff, **Edwards, III, C.K.**, A. Solinger, M. Macri, and T. Joh. 2005. A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I (Pegsunercept) in Rheumatoid Arthritis patients. *J. Rheumatology*. 32:2303-10.
88. Li, Y-Y. Y, J-F. Chang, Y. Yang, C. Garrison Fathman, M. Bao, **Edwards, III, C.K.**, and J.R. Parnes. 2004. Murine splenic B lymphocyte activation using different activation stimuli induces in vitro splicing of Tumor Necrosis Factor- α nuclear pre mRNA. *Molecular Immunol*. 43:613-622.
89. Li, Q., L. Li, W. Shi, X. Jiang, Y. Xu, F. Gong, M. Zhou, **Edwards, III, C.K.** and Z. Li. 2006. Mechanism of action difference in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo. *Cancer Immunol. Immunotherapy*. 55:1470-9.
90. Wang, X., Hsu, H.C., Wang, Y., **Edwards, III, C.K.**, Yang, P. Wu, Q., Mountz, J.D. 2006. Phenotype of genetically regulated thymic involution in young BXD RI strains of mice. *Scan. J. Rheum*. 64: 287-94.
91. Schottelius, A.J.G., K. Asadullah, W. Steery, and **Edwards, III, C.K.** .2008. Anti-TNF α therapy in Dermatology. *TRENDS Immunol. In the Press*.
92. Kosontini, R., M. Nowak, J.J. Rosenberg, **Edwards, III, C.K.**, L.L. Moldawer, and S.L.D. MacKay. 2009. Endogenous TNF- α production protects against Fas Ligand induced liver injury through a NF- κ B dependent pathway. *Journal of Immunology. In the Press*.

93. Colagiovanni, D.B., R. Ksontini, R.J. Evans, G. Kieft, T. Kohno, J. Spellberg, T. Zhou, J.D. Mountz, A.M. Bendele, S. Wooden, U. Selvanayaga, S. Hu, M. Clare-Salzler, H. Bluethmann, L.L. Moldawer, and **Edwards, III, C.K.** 2009. Tumor Necrosis Factor- α and fas ligand interactions during lipopolysaccharide/D-galactosamine-induced shock. *American Journal of Physiology*. *In the Press*.
94. **Edwards, III, C.K.** 2009. Pegsunercept: A high-affinity, recombinant E. coli-derived, human soluble tumor necrosis factor type I [p55] monomeric receptor designed for chronic inflammatory diseases. *J. Controlled Release*. *In the Press*.
95. Hamada, K., E. Vannier, T. Yamada, D.E. Smith, L.W. Abad, M. Tokuriki, **Edwards, III, C.K.**, J.G. Cannon, and R. Roubenoff. 2007. Inflammatory cachexia regulates sarcoactive cytokine gene expression in rat skeletal muscle tissue. *Journal of Rheumatology*. *34*: 1817-22.
96. **Edwards, III, C.K.**, A.M. Bendele, L.I. Reznikov, G. Fantuzzi, E.S. Chlipala, L. Li, L.L. Moldawer, J.D. Mountz, Y.-Y. Y. Li, and C.A. Dinarello. 2006. Soluble human TNF p55 and p75 receptors reverse spontaneous arthritis in transgenic mice expressing transmembrane TNF- α . *Arthritis & Rheumatism*. *54*: 287-85.
97. **Edwards, III, CK**, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Feige U, Kohno T. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. *Advanced Drug Delivery Reviews: Site Specific PEGylation of Polypeptides*. 2003; *55*:1315-1336.
98. **Edwards, III, CK**. Drug discovery and development for inflammatory diseases: Meeting highlights. *Expert Opin. Ther. Targets*. 2004; *8*:151-163.
99. Schottelius AJG, Moldawer LL, Dinarello CA, Asadullah K, Steery W, **Edwards, III, C.K.** Biology of Tumor Necrosis Factor- α (TNF- α): Implications for psoriasis. *Experimental Dermatology*. 2004; *13*:193-222.
100. Lundberg, P, Welander, PV, **Edwards, III, C.K.**, van Roojen, N, Cantin, E. Tumor necrosis factor (TNF) protects resistant C57Bl/6 mice against Herpes Simplex Virus encephalitis independently of signaling via TNF receptor 1 or 2. *J Virology*. 2007; *81*:1451-1460.
101. Riemann, H. J. Takao, Shellman, Y.C., Hines, W.S., **Edwards, III, C.K.**, Franzusoff, Norris, D.A., Fujita, M.D. 2007. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. *Exp. Dermatol.* *17*:814-22.
102. Francis, S.O., **Edwards, III, C.K.** 2008. You and your cytokines. *National Psoriasis Foundation Forum*. *15*:22-23.
103. Wang X, Fujita M, Prado, R, Tousson A, Hsu H, Kelly DR, Yang PA, Chen J, Xu H, Elmets CA, Mountz JD, **Edwards, III, CK**. 2009. Visualizing CD4⁺ T cell migration into inflamed skin and its inhibition by CCR4/CCR10 blockades using in vivo imaging model. *Br J Dermatol*. [Epub ahead of print]
104. Rooney T, **Edwards III CK**, Gogarty M, Greenan L, Roux-Lombard P, Veale DJ, FitzGerald O, Dayer J-M, Bresnihan B. 2010. Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis. Observations from a proof-of-concept randomized clinical trial of cytokine blockade. *Rheumatol. Int.* (Epub ahead of press).
105. Hu L.-J.*, Francis S.O.*, Li L.; Fujita, M., Fitzpatrick J.E., Rengasamy, A., Shroyer, K., Azam, T.; Helm, K., Kim, S.-H., Dinarello, C.A., Norris, D.A., and **Edwards, III, C.K.** Autoreactive CD4⁺CD45RO⁺CCR4⁺ CCR10⁺ Th22 Memory T Cells Activate Keratinocytes to Produce the Proinflammatory Cytokine IL-32 γ in a Cell-Cell Contact Manner. *J. Clin. Invest* (Communicated 2011).
106. Li L*, Callaway E, Liu B, Fujita M., D. Rengasamy A, Hu L-J, Fitzpatrick D, Francis SO, Zhu M, Burger D, Dayer J-M, Dinarello CA, Norris DA, and **Edwards, III, C.K.** Dissociation of human T-cell mediated macrophage activation to produce proinflammatory cytokines by CD40 ligand (CD154), IFN γ , or novel T-cell cytokine inducing surface molecules (TCISMs). *Nature Biotechnology* (Communicated 2011).
107. Fujita, M.*, Jonscher, K.R., Li, L., Eisenmesser E.Z., Schelegel, J., Rengasamy A., Radzic, J., Fujita M., Norris D.A., and **Edwards, III, C.K.**[#] Specific interactions between *cis/trans*-prolyl isomerase FKBP52 and CD147:EMMPRIN mediate human T-cell driven macrophage activation and proinflammatory cytokine production in a cell-cell contact manner. *Science*. (Communicated 2011).

108. Li, L.*, Jonscher KJ*, Fujita, M., Eisenmesser EZ, Schneidewind B., Schlegel J, Redzic J, Armstrong G., Francis SO, Hu L-J, Zhu M, Norris DA, and **Edwards, III, C.K.**[#] FKBP52, an immunophilin with cis/trans proyl-isomerase activity, is upregulated in CLA Ag⁺, CD4⁺CD45RO⁺CCR4+CCR10⁺ Th22 T cells obtained from patients with psoriasis vulgaris: implicated roles in T cell-mediated Mφ activation via the EMMPRIN pathway. *Blood (Communicated 2011)*.
109. Rengasamy, A.*, Akana, H., Eisenmesser, E.Z., Schlegel, J., Fujita, M., **Edwards, III, C.K.**[#] Cyclophilins A/B, FK binding protein 52 (FKBP52), and Soluble EMMPRIN-Ligand: Interleukin-39 (IL39) stimulates Mφ to secrete the proinflammatory cytokines TNFα, IL1β, IL32γ, IL17A, and IL23 via interactions with membrane-bound EMMPRIN: Reversal by a natural soluble EMMPRIN Inhibitor. *Immunity (Communicated 2011)*.
110. **Edwards, III, C.K.**^{*}, Rengasamy A., and Eisenmesser, E.Z.[#] Soluble EMMPRIN Ligand: Interleukin-39: A novel proinflammatory cytokine with potent cytokine-inducing activity on human Mφ and CD4⁺ Memory T cells. *Immunity. (Communicated 2011)*.

(iii.) Manuscripts in Preparation:

1. **Edwards, III, C.K.** A. Welcher, N.S. Chow, R.F. Baltera, D.M. Miller, M.J. Gresser, C.A. Dinarello, and M.P. Bevilacqua. 2011. Selective inhibition of IL-1β induced proinflammatory gene expression by recombinant IL-1 receptor antagonist (IL-1ra; Anakinra) in human whole blood cultures: contrast to other anti-inflammatory agents. *Arthritis Rheum. In preparation.*
2. Francis, S.O. C.A. Dinarello, V.A. Marsh, D.B. Trollinger, D.A. Norris, and **Edwards, III, C.K.** 2011. Inhibition of proinflammatory gene expression by soluble TNF receptors in human whole blood cultures: Marked contrast between TNF p55 receptor (Pegsunercept) and TNF p75 receptor (Etanercept). *Arthritis Rheum. In preparation.*
3. **Edwards, III, C.K.**, D. Trollinger, G.-R. Burmeister, H-D Volk, M. Schiff, M., B.L. Kotzin, H. Mitsuya, T. Kawaguchi, K-M. Sakata, D.A. Norris and C.A. Dinarello. 2011. Anti-tumor necrosis factor-α therapy in a defined subpopulation of rheumatoid arthritis patients reduces inflammatory gene expression in whole blood in comparison to standard DMARD therapy alone. *Arthritis Rheum. In preparation.*
4. **Francis, S.O.** L-J. Hu, C.A. Dinarello, D.A. Norris and **C.K. Edwards, III.** 2011. Critical roles of the proinflammatory cytokines interleukin-32γ, tumor necrosis factor-α (TNFα) and interleukin-1 in cutaneous inflammation. *J. Invest. Dermatol. In preparation.*

B. Peer-Reviewed Books, Book Chapters, and Symposium Proceedings:

1. Johnston, Jr., R.B., S. Kitagawa, **Edwards, III, C.K.**, J.Y. Channon, L.L. Suzuki and M.B. Pabst. 1988. The respiratory burst in activated macrophages: Studies of its molecular basis and evidence for down-regulation in immunomodulation to intracellular pathogens. In T.K. Eisenstein (Ed.) Host Defenses and Immunomodulation to Intracellular Pathogens. Plenum Press. New York, NY. pp. 63-72.
2. Johnston, Jr., R.B., **Edwards, III, C.K.**, J.Y. Channon, M. Sasada, K. Yamamoto, S. Kitagawa and M.J. Pabst. 1988. The generation of toxic oxygen metabolites by phagocytic cells: Possibilities for pharmacologic regulation at sites of inflammation. In K. Kawai (Ed.) Cytoprotection and Cytobiology, Volume 5. Excerpta Medica. Tokyo, Japan. pp. 11-30.
3. **Edwards, III, C.K.**, J.M. Schepper, L.M. Yungler and K.W. Kelley. 1988. Somatotropin and prolactin enhance respiratory burst activity of macrophages. In C.S. Raines (Ed.) Second International Congress of Neuroimmunology / Neuroimmunomodulation. Annals of the New York Academy of Sciences. New York, NY. pp. 698-699.
4. Kelley, K.W. and **Edwards, III, C.K.** 1989. Macrophages as targets for one action of somatotropin. In J.W. Hadden, K. Masek, and G. Nistlon (Eds.). Interactions among Central Nervous System, Neuroendocrine and Immune Systems. Pythagora Press. Rome, Italy. pp. 165-176.
5. Kelley, K.W. and **C.K. Edwards, III.** 1989. Effects of somatotropin on the immune system. In P. van der Wal, G.J. Nieuhof and R.D. Politiek (Eds.) Biotechnology for Control of Growth and Product Quality in Swine: Implications and Acceptability. Pudoc Wageningen. The Netherlands. pp. 145-153.
6. Kelley, K.W. and **Edwards, III, C.K.** 1994. Neuroendocrinological regulation of autoimmunity.

- In Proceedings of the 8th International Congress of Immunology. Academic Press. New York, NY.
7. **Edwards, III, C.K.**, S. Borchering, J. Zhang and D.R. Borchering. 1994. The role of tumor necrosis factor- α (TNF α) in acute and chronic inflammatory processes: Novel therapeutic approaches. In L.B. Schook and D. Laskin (Eds.) *Xenobiotic-Induced Inflammation: Role of Cytokines and Growth Factors*. Academic Press. New York, NY. pp. 97-147.
 8. Mountz, J.D., **Edwards, III, C.K.** J. Cheng, P. Yang, A. Wang, C. Liu, X. Su, H. Bluethmann, and T. Zhou. 1996. Autoimmunity due to defective Nur77, *fas*, and TNF-RI apoptosis. In Gupta and Cohen (Eds.). *Mechanisms of Lymphocyte Activation and Immune Regulation VI*. Plenum Press, New York, NY. pp. 241-262.
 9. Mountz, J.D., T. Zhou, X. Su, J. Cheng, M. Pierson, H. Bluethmann, and **Edwards, III, C.K.**. 1996. Autoimmune disease results from multiple interactive defects in apoptosis induction molecules and signaling pathways. In P. Krammer (Ed.) *Apoptosis*. Behring Institute Research Communications. 97: 200-219.
 10. **Edwards, III, C.K.** 1997. Novel therapeutic strategies utilizing cytokine antagonists for inflammatory diseases. In J.L. Vincent (Ed). *Update in Intensive Care and Emergency Medicine*. Springer-Verlag, Berlin, Germany.
 11. Ksontini, R., C.L. Tannahill, D.B. Colagiovanni, **Edwards, III, C.K.**, Z. Abouhamze, J-N. Vauthey, E. M. Copeland, III, L.L. Moldawer, and S. L.D. MacKay. 1997. Activation of the *fas/fasL* pathway induces a TNF α response that attenuates *fasL* mediated liver injury. In: *Surgical Forum: Conference Proceedings*. Academic Press, New York, NY.
 12. Mountz, J.D., T. Zhou, H. Bluethmann, and **Edwards, III, C.K.** 1997. Fas and TNF-RI down-modulate macrophage-T-cell interaction and limit the immune response. In: *Proceedings of the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis-Mechanism and Therapeutic Approaches*. March 4-8, 1997, Munich, Germany. Moduzzi Editore S.p.A. Bologna, Italy. pp. 1041-1046.

C. Invited Speaking Presentations at Scientific Conferences (*Denotes author who presented paper).

1. *Gangadharam, P.R.J., P.F. Pratt and C.K. **Edwards, III**. 1984. Animal models for Mycobacterium intracellulare. In F.M. Collins (Ed.) *Proceedings 19TH Joint Conference of US-Japan Panels on Tuberculosis and Leprosy*. NIH Press. Bethesda, MD. 8:128-154.
2. **Edwards, III, C.K.**, M.J. Jacobs and P.M. Keith. 1986. RALs and the immune response. In *Managing in Changing Times*. IMC Conference Proceedings. Veterinary Products Division Press. Northbrook, IL. 9:59-88.
3. ***Edwards, III, C.K.**, L.M. Yunger and K.W. Kelley. 1987. The role of somatotropin in swine health and disease. In G. Hollis (Ed.) *University of Illinois Pork Industry Conference Proceedings*. *University of Illinois Press*. Urbana, IL. 12:105-125.
4. *Kelley, K.W. and C.K. **Edwards, III**. 1988. Macrophages as targets for one action of somatotropin. In *Proceedings of the International Symposium on Interactions between the Neuroendocrine and Immune Systems*. Catanzaro, Italy.
5. ***Edwards, III, C.K.** and K.W. Kelley. 1988. Somatotropin as an immunomodulator in swine. In *Proceedings of the International seminar on the Science of Porcine Somatotropin*. *Pitman-Moore, Inc. Press*. pp. 59-74.
6. *Kelley, K.W. and C.K. **Edwards, III**. 1988. Growth hormone primes macrophages for production of superoxide anion. In *Progress in Neuroendocrinimmunology (PNEI), First International Conference*. *Progress in Neuroendocrinimmunology*. 1:11-12.
7. *Kelley, K.W. and C.K. **Edwards, III**. 1989. Effects of somatotropin on the immune system. In *Symposium for Biotechnology for Control of Growth and Product Quality in Swine: Implications and Acceptability*. Pudoc. Wageningen. The Netherlands. pp. 145-153.
8. ***Edwards, III, C.K.** 1991. The use of immunomodulating agents to regulate MHC class II antigen expression in transgenic animal models. *Presented at* MHC and TCR in Autoimmune Diseases Symposium and Workshop. *The Jackson Laboratory*. Bar Harbor, ME. (October 18-20).
9. ***Edwards, III, C.K.**, J. Zhang, T. Zhou, M. De, R.E. Long, D.R. Borchering and J.D. Mountz. 1992.

- Evidence of a proinflammatory role for TNF α in a transgenic model of superantigen-induced arthritis. *Presented at the 4th International TNF Congress*. Koningshof. Veldhoven. The Netherlands. (May 2-6, 1992). *European Cytokine Network*. 3:260.
10. Zhang, J., T.J. Baker, T. Zhou, R.E. Long, J.D. Mountz and ***C.K. Edwards, III**. 1992. Enhanced production of proinflammatory cytokines and MHC class II antigen expression by macrophages treated with bacterial superantigens. *Presented at the American College of Rheumatology Annual Meeting*. Atlanta, GA (October 10-15, 1992). *Arthritis and Rheumatism*. 35:549.
 11. Zhang, J., T. Zhou, J.D. Mountz and ***C.K. Edwards, III**. 1993. Defective *fas* antigen gene expression in peritoneal macrophages from aged MRL-*lpr/lpr* autoimmune mice correlates to enhanced TNF- α production. *Presented at the American Association of Immunologists Annual Meeting*. Denver, CO (May 21-25, 1993). *Journal of Immunology*. 150:85A.
 12. ***Edwards, III, C.K.**, T. Zhou, J. Zhang, C.D. McWhinney, T.L. Bowlin and J.D. Mountz. 1993. Elevated proinflammatory cytokine production by macrophages obtained from aged MRL-*lpr/lpr* autoimmune mice correlates to defective *fas* antigen gene expression. *Presented at the American College of Rheumatology Annual Meeting*. San Antonio, TX (November 7-11, 1993). *Arthritis and Rheumatism*. 36:561. (Abstract 138).
 13. ***Edwards, III, C.K.**, C.M. Cullen, P.F. Bonventre, H. Heeg, J.F. French, H. Bluethmann and J.D. Mountz. A *fas* antigen mutation allows development of toxic shock syndrome toxin-1 (TSST-1)-induced lethal shock in V β 8.2 T-cell receptor transgenic mice. *Presented at the American College of Rheumatology Annual Meeting*. Minneapolis, MN (October 23-27, 1994). *Arthritis and Rheumatism* 37:S284 (Abstract 746).
 14. ***Edwards, III, C.K.**, C.M. Cullen, P.F. Bonventre, H. Bluethmann, T. Zhou and J.D. Mountz. 1995. Superantigen-induced lethal shock in V β 8.2 T-cell receptor transgenic mice is regulated by a *fas* apoptosis receptor (*fasR*) mutation. *Presented at the 9th International Congress of Immunology*, July 23-29, 1995.
 15. ***Edwards, III, C.K.** 1995. Recombinant human tumor necrosis factor-binding protein (TNF-bp): A novel, high-affinity soluble inhibitor of tumor necrosis factor- α . *Presented at the Second Annual Inflammatory Cytokine Antagonists Conference* (sponsored by Cambridge Healthcare Institute), November 13-15, 1995. Boston, MA.
 16. ***Edwards, III, C.K.** 1996. The effects of recombinant human tumor necrosis factor-binding protein (TNF-bp) in animal models of acute and chronic inflammation. *Presented at the Second Annual Sepsis/SIRS Conference*, "Designing Better Drugs & Clinical Trials for Reducing Mortality to Patients and Suppliers", February 12-13, 1996. Washington, D.C.
 17. *Mountz, J.D., T. Zhou, **C.K. Edwards, III**, and H. Bluethmann. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in *lpr* mice lacking tumor necrosis factor receptor I. *Presented at the 6th International TNF Congress*. Rhodes, Greece. *European Cytokine Network*. 7: 237 (Abstract 129).
 18. ***Edwards, III, C.K.** 1996. Tumor Necrosis Factor Binding Protein (TNF-bp). *Presented at the Amgen Oncology Fellows Program Review*. June 7-8, 1996. Thousand Oaks, CA.
 19. ***Edwards, III, C.K.** 1996. *In vitro* and *in vivo* anti-inflammatory effects of a high-affinity soluble inhibitor of tumor necrosis factor- α , recombinant human tumor necrosis factor-binding protein (TNF-bp). *Presented at the third annual "Cytokine Therapeutics: A review & future therapeutic applications"*. An IBC International Conference, June 11-12, 1996. The Royal Society, London, UK.
 20. ***Edwards, III, C.K.**, T. Zhou, J.G. McCabe, R.E. Long, D.R. Borchering, T.L. Bowlin, H. Bluethmann, and J.D. Mountz. 1996. Inhibition of inflammatory arthritis in *fas* mutant aged MRL-*lpr/lpr* mice by TNF α antagonists. *Presented at the First International Conference on Immunology and Aging*. Natcher Conference Center, National Institutes of Health, Bethesda, MD. June 16-19, 1996. NIH Press 1:33 (Abstract S-5).
 21. ***Edwards, III, C.K.** 1996. Novel synthetic and recombinant protein strategies for antagonizing TNF α (Symposium Chairman). *Presented at the IBC Sixth Annual International Symposium on Sepsis: Advances in Treatment and Drug Development*, June 24-26, 1996. Cambridge, MA.
 22. Zhou, T., **C.K. Edwards, III**, H. Bluethmann, and *J.D. Mountz. 1996. *Fas* and tumor necrosis factor-

- receptor I-mediated activation-induced cell death of macrophages. *Presented at* the 60th National Scientific Meeting of the American College of Rheumatology. ACR Abstract session 10 “Cytokines”, October 19, 1996.
23. ***Edwards, III, C.K.** 1996. Anti-cytokine strategies directed to block surface-membrane receptors. *Presented at* the Symposium of Surgical Infections: Local interfaces and Systemic Responses. October 24-25, 1996. Madrid, Spain.
 24. ***Edwards, III, C.K.** 1997. Tumor Necrosis Factor Binding Protein (TNF-bp) (Symposium Chairman). *Presented at* the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis. March 4-8, 1997. Munich, Germany.
 25. ***Edwards, III, C.K.** 1997. Dual functions of TNF: Anti-inflammatory effects resulting from apoptosis (AICD). *Presented at* “Immunopathology of mucous membranes and exocrine glands”. May 13-16, 1997. Bergen, Norway.
 26. ***Edwards, III, C.K.** 1997. Involvement of *fas* ligand (*fasL*) in LPS-induced septic shock using *fas*-deficient MRL-*lpr/lpr* mice: Concomitant proinflammatory effects with TNF- α . *Presented at* the 5th Annual Conference of the International Cytokine Meeting. November 9-13, 1997. Lake Tahoe, NV.
 27. ***Edwards, III, C.K.** 1998. A high-affinity p55 sTNF-RI receptor antagonist as a potential therapeutic for chronic inflammatory disease. *Presented at* TNF Antagonism: A Viable Target for Drug Development Conference. Sponsored by Strategic Research Institute (SRI). February 25-26, 1998. Miami, FL.
 28. ***Edwards, III, C.K.** 1998. Soluble tumor necrosis factor receptor type I (sTNF-RI): A novel therapeutic designed for chronic inflammatory diseases. *In*: Anti-TNF-Alpha Therapeutic Strategies. Second Joint Meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research. Jerusalem, Israel, October 25-30, 1998.
 29. ***Edwards, III, C.K.** 1999. The effects of Interleukin-1 receptor antagonist (IL-1ra) and soluble tumor necrosis factor receptor type I (sTNF-RI) in inflammatory diseases. First Annual Meeting TNF- α in Therapeutic Strategies for Clinical Medicine. Half Moon Bay, Jamaica. March 25-30, 1999.
 30. *Bendele AM, Chlipala ES, Rich WR, **Edwards III CK.** Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-1ra) and PEGylated recombinant human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in animal models of rheumatoid arthritis. *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*.
 31. *Tornwald J, Fox H, **Edwards, CK, III,** Fox, RI. Treatment with PEGylated recombinant methionyl human soluble tumor necrosis factor-type I receptor (PEG sTNF-RI) prevents development of Sjogren’s syndrome and diabetes in the NOD mouse model. *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*.
 32. ***Edwards, III, C.K.** Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-1ra) and PEGylated recombinant human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in animal models of RA. *Presented at* the 9th APLAR Congress of Rheumatology Meeting, Beijing, China May 22, 2000.
 33. ***Edwards, III, C.K.** EULAR Annual Meeting, Nice, France, Amgen Satellite Symposium “A Biological Approach to Rheumatoid Arthritis Treatment: Targeted Interleukin-1 Inhibition”. June 23, 2000.
 34. **Edwards, III, C.K.** Targeted Therapies in Rheumatology, Interleukin-1 Receptor Antagonist (IL-1Ra): An Update”, Nassau, the Bahamas. April 28, 2001.
 35. ***Edwards, III, C.K.** Japanese Rheumatism Association, “Combination immunotherapy with PEGylated sTNF-RI and IL-1Ra”, Tokyo, Japan, May 19, 2001.
 36. ***Edwards, III, C.K.** EULAR International Rheumatology Conference, “Anticytokine-based therapies for Rheumatoid Arthritis”, June 13-17, 2001.
 37. ***Edwards, III, C.K.** 11th International Congress of Immunology, “Combination immunotherapy with IL-1Ra and TNF Receptors”, Stockholm, Sweden, July 25, 2001.
 38. **Edwards, III, C.K.** International League of Arthritis and Rheumatism (ILAR), “Efficacy for cartilage damage with chronic arthritis by potential combination of sTNF-RI and IL-1RA”, Edmonton, Canada, August 15, 2001.

39. **Edwards, III, C.K.** Macrophages in Autoimmune Diseases International Conference, “Use of Pharmacogenomics to differentiate p75 and p55 Soluble TNF Receptors”, Melbourne, Australia, February 2, 2002.
40. **Edwards, III, C.K.** 3rd International Congress of Autoimmunity, “Costimulation molecules in Autoimmune Diseases”, Geneva, Switzerland, February 23, 2002.
41. **Edwards, III, C.K.** IBC 2nd International Conference, Drug Discovery and Development for Inflammatory Diseases, “Assessing the progress of small molecule inhibitors to modulate cytokines”, Copenhagen, Denmark, October 7, 2003.

D. Abstracts (*Denotes author who presented paper).

1. ***Edwards, III, C.K.,** P.F. Pratt and P.R.J. Gangadharam. 1982. Release of superoxide anion from resident and activated peritoneal macrophages following exposure to *Mycobacterium intracellulare*. American Society for Microbiology Rocky Mountain Branch. Annual Meeting Proceedings. Golden, CO. Abstract 25.
2. ***Gangadharam, P.R.J.,** P.F. Pratt and C.K. **Edwards, III.** 1982. Pathogenicity of *M. intracellulare* to hydrogen peroxide and peroxidative killing mechanisms. 17th US-Japan Cooperative Conference on Tuberculosis. NIH Press. Bethesda, MD. p. 135.
3. ***Edwards, III, C.K.,** P.F. Pratt, P.S. Murthy and P.R.J. Gangadharam. 1982. Evaluation of an acute infection model for *M. intracellulare*. American Society for Microbiology Rocky Mountain Branch. Annual Meeting Proceedings. Fort Collins, CO. Abstract 10.
4. ***Gangadharam, P.R.J., C.K. Edwards, III** and P.F. Pratt. 1982. Experimental short-course chemotherapy for *M. kansasii* disease. World Tuberculosis Conference. Buenos Aires, Argentina. Abstract 37.
5. ***Edwards, III, C.K.,** and P.R.J. Gangadharam. 1983. Release of superoxide anion and hydrogen peroxide from peritoneal macrophages of mice challenged with *M. intracellulare*. Abstracts of Annual Meeting of the American Thoracic Society. Kansas City, MO. *American Review of Respiratory Diseases.* 127:197.
6. ***Gangadharam, P.R.J. and C.K. Edwards, III.** 1983. An acute infection mouse model for *M. intracellulare* disease. In Abstracts of Annual Meeting of the American Thoracic Society. Kansas City, MO. *American Review of Respiratory Diseases.* 127:196.
7. ***Gangadharam, P.R.J.,** P.F. Pratt and C.K. **Edwards, III.** 1983. Animal models for *M. intracellulare* disease. Abstracts of the 18th US-Japan Cooperative Conference on Tuberculosis. Bethesda, MD. NIH Press. p. 128.
8. ***Howard, D.K.,** E.R. Clough, A.F. Abruzzini and C.K. **Edwards, III.** 1986. Cell culture applications to veterinary immunology. Annual Meeting of the Midwest Tissue Culture Association. Chicago, IL. Abstract 47.
9. ***Keith, P.M.,** A.F. Abruzzini, E.R. Clough, C.K. Edwards, III, and D.K. Howard. 1986. Immune stimulants: Potential applications in veterinary medicine. Abstracts of the National Meeting of the American Chemical Society. *Journal of the American Chemical Society.* Abstract 426.
10. ***Edwards, III, C.K.,** M.J. Jacobs, P.M. Keith, D.M. Meyers, C.A. Power and L.M. Younger. 1986. Activation of murine peritoneal and alveolar macrophages with a zearalane derivative. In Abstracts of the 6th International Congress on Immunology. *Progress in Immunology.* Volume VI. p. 167.
11. ***Ivy, R.E.,** G.W. Wolfrom and C.K. **Edwards, III.** 1986. Effects of growth hormone and ralgro (zeranol) in finishing beef cattle. In Abstracts of the 78th Annual American Society of Animal Science National Meeting. Kansas City, MO. *Journal of Animal Science.* 63:217.
12. ***Edwards, III, C.K.,** D.M. Meyers, W. Cain and P.M. Keith. 1986. Effect of FK565, an immunoreactive peptide, on host resistance to infection and macrophage superoxide anion release. In Abstracts of the Society for Industrial Microbiology Annual Meeting. A-21.
13. ***Edwards, III, C.K.,** J.M. Schepper, L.M. Younger and K.W. Kelley. 1987. Somatotropin and prolactin enhance the respiratory burst activity of macrophages. Second International Congress of Neuroimmunology. *Journal of Neuroimmunology.* 16:49.
14. ***Abruzzini, A.F.,** J.P. Mueller and C.K. **Edwards, III.** 1987. Recombinant human interleukin-2

- directly stimulates bovine leukocytes and initiates the bovine lymphokine cascade. In Abstracts of the Argonne Winter Conference on Biotechnology Directions: Biomolecules. Argonne National Laboratories Press. Chicago, IL. Abstract 22.
15. ***Edwards, III, C.K.**, S.M. Ghiasuddin, R.M. Lorrence, J.M. Schepper, L.M. Yunger, and K.W. Kelley. 1988. Somatotropin augments expression of MHC class II antigens and release of tumor necrosis factor- α . *FASEB Journal*. 2:A1452.
 16. *Davila, D.R., **C.K. Edwards, III** and K.W. Kelley. 1988. Syngeneic pituitary grafts augment IL-2 synthesis, spontaneous splenocyte proliferation, thymic size and production of tumor necrosis factor in aged rats. *FASEB Journal* 1:A1642.
 17. *Myers M.J. **C.K. Edwards, III**, J.F. Lockwood, K.W. Kelley and L.B. Schook. 1989. Changes in the production of macrophage reactive oxygen intermediates (ROI) following dimethylnitrosamine (DMN) exposure. *The Toxicologist* 9:39.
 18. ***Edwards, III, C.K.**, R.M. Lorrence, D.M. Dunham, L.M. Yunger and K.W. Kelley. 1989. Peritoneal macrophages from hypophysectomized rats treated with interferon- γ or growth hormone are primed to release tumor necrosis factor- α . In 7th International Congress on Immunology, *Progress in Immunology*. Volume VII. 93:20.
 19. ***Edwards, III, C.K.**, R.M. Lorrence, L.M. Yunger and K.W. Kelley. 1989. Rats treated with interferon- γ or growth hormone have enhanced protection to *Salmonella typhimurium*. Society for Leukocyte Biology (RES Society) Annual Meeting. *Journal of Leukocyte Biology*. 46:293.
 20. ***Edwards, III, C.K.**, R.M. Lorrence, R.J. Walter, K.W. Kelley, L.M. Yunger and J.A. Greager. 1989. Augmentation of endotoxin-induced necrosis of tumors and priming of macrophages for tumor necrosis factor production by growth hormone. Second International Workshop on Cytokines. Hilton Head, SC. *Cytokine* 1:104.
 21. *Lorrence R.M., **C.K. Edwards, III**, R.J. Walter, J.A. Greager, S.J. Manos, L.M. Yunger and K.W. Kelley. 1989. Antitumor properties of growth hormone and interferon- γ : Augmentation of endotoxin-induced necrosis of murine tumors. In: Abstracts of American Federation for Clinical Research. Society for Investigative Dermatology. *Clinical Research*. Abstract 22.
 22. ***Edwards, III, C.K.**, S. Arkins, D.P. Bane, W.F. Hall, R.M. Lorrence and K.W. Kelley. 1990. Growth hormone enhances bacterial killing by alveolar macrophages. *FASEB Journal*. 4:A1754.
 23. *Zhou T., H. Bluethmann, R.E. Gay, **C.K. Edwards, III** and J.D. Mountz. 1991. A superantigen model for arthritis in V β 8.2 TCR transgenic MRL-*lpr/lpr* mice. Presented at Keystone Symposia on Molecular and Cellular Biology: Molecular Biology and the Immunopathogenesis of Rheumatoid Arthritis, Lake Tahoe, NV, March 15-21, 1991. *Journal of Cellular Biochemistry*. 15E: 145.
 24. ***Edwards, III, C.K.**, L.M. Watts, M.D. Hatfield and D.R. Borcharding. 1991. Down-regulation of MHC class II antigen expression on macrophages by adenosine and related analogs. Presented at Keystone Symposia on Molecular and Cellular Biology: Molecular Biology and the Immunopathogenesis of Rheumatoid Arthritis, Lake Tahoe, NV, March 15-21, 1991. *Journal of Cellular Biochemistry*. 15E: 155.
 25. *Parmely M.J., **C.K. Edwards, III**, D.R. Borcharding and D.C. Morrison. 1991. Adenosine and related analogs selectively inhibit TNF- α production by mouse macrophages. *FASEB Journal* 5:A1602.
 26. ***Edwards, III, C.K.**, T. Zhou, D.R. Borcharding, R.E. Long, H. Bluethmann and J.D. Mountz. 1991. Effects of Cyclosporin A, adenosine and related analogs on Staphylococcus *enterotoxin B*-induced autoimmune disease in V β 8.2 T-cell receptor transgenic MRL-*lpr/lpr* mice. Presented at 2nd Congress on Immunointervention in Autoimmune Diseases: The Role of Sandimmun. Paris, France, May 13-16, 1991. *Journal of Autoimmunity* 5 :(Supplement A); 372.
 27. *Mountz, J.D., H. Bluethmann, R.E. Gay, **C.K. Edwards, III** and T. Zhou. 1991. A superantigen model for arthritis in V β 8 TCR transgenic *lpr/lpr* mice. Presented at the American Society for Clinical Investigation. *Clinical Research* Vol. 39:340A.
 28. *Parmely M.J., W. Zhou, **C.K. Edwards, III**, D. Borcharding, R.S. Silverstein and D.C. Morrison. 1991. Adenosine and its analogs selectively inhibit TNF- α production and protect mice against lethality. In Progress in Leukocyte Biology. Third International Workshop on Cytokines. Stresa, Italy. November 10-14, 1991. *Cytokine*. 5:502.

29. *Zhang, J., Z.H. Ye, T. Zhou, J.D. Mountz and **C.K. Edwards, III**. 1991. Tumor necrosis factor- α (TNF- α) acts as an immunomodulator in *Staphylococcus enterotoxin B*-induced autoimmune disease in MRL-*lpr/lpr* mice. Presented at the American College of Rheumatology Annual Meeting. Boston, MA. November 17-21, 1991. *Arthritis and Rheumatism*. 34 (supplement): 117.
30. *Mountz, J.D., T. Zhou, R. Gay, S. Gay, W.J. Koopman, H. Bluethmann, R.E. Long and **C.K. Edwards, III**. 1991. Genetic and environmental requirements for development of inflammatory arthritis. Presented at the American College of Rheumatology Annual Meeting. Boston, MA. November 17-21, 1991. *Arthritis and Rheumatism*. 34(supplement): S61.
31. *Mountz, J.M., T. Zhou, J. Harris, **C.K. Edwards, III** and J.D. Mountz. 1991. Application of ultra-high resolution ^{99m}Tc MDP bone scanning to animal models of arthritis. Presented at the American College of Rheumatology Annual Meeting. Boston, MA. November 17-21, 1991. *Arthritis and Rheumatism*. 34(supplement): S68.
32. Mountz, J.D., *T. Zhou, **C.K. Edwards, III** and H. Bluethmann. 1991. Loss of neonatal-induced tolerance to a superantigen results in severe autoreactivity in autoimmune mice. Presented at the American College of Rheumatology Annual Meeting. Boston, MA. November 17-21, 1991. *Arthritis and Rheumatism*. 34 (supplement): S38.
33. *Long, R.E., T.J. Baker, J. Zhang and **C.K. Edwards, III**. 1991. Histopathologic assessment of knee joint changes over time in the Lewis (LEW/N) rat antigen-induced arthritis (AIA) model. Presented at the American College of Veterinary Pathologists Annual Meeting. Chicago, IL. December 10-12, 1991. *American journal of Veterinary Pathology*. Supplement. Abstract 47.
34. ***Edwards, III, C.K.**, M.J. Parmely, D.R. Borcharding and D.C. Morrison. 1991. Adenosine and related analogs use different mechanisms to inhibit IFN- γ priming of macrophages for enhanced respiratory burst. Presented at the 28th Annual Meeting of the Society for Leukocyte Biology. Aspen, CO. September 28-October 1, 1991. *Journal of Leukocyte Biology*. 2 (supplement): 54.
35. ***Edwards, III, C.K.**, T. Zhou, J. Zhang, R.E. Long, D.R. Borcharding and J.D. Mountz. 1992. Use of disease modifying agents to elucidate pathogenic mechanisms in superantigen-induced arthritic V β 8.2 T-cell receptor MRL-*lpr/lpr* mice. Presented at Keystone Symposia "Antigen Presentation Functions of the MHC". Taos, NM. March 5-11, 1992. *Journal of Cellular Biochemistry*. 16D (supplement): 46.
36. *Mountz, J.D., T. Zhou, H. Bluethmann and **C.K. Edwards, III**. 1992. Autoreactive T-cells result from increased co-stimulatory signaling in TCR transgenic *lpr/lpr* mice. Presented at Keystone Symposia "Antigen Presentation Functions of the MHC". Taos, NM. March 5-11, 1992. *Journal of Cellular Biochemistry*. 16D (supplement): 52.
37. De, M., T.J. Baker, R.E. Long, L.M. Watts, G.W. Wood, J.D. Mountz and ***C.K. Edwards, III**. 1992. Evaluation of pro-inflammatory cytokine gene expression in Lewis/N rat antigen-induced arthritis. Presented at the Federation of American Society for Experimental Biology Annual Meeting. Anaheim, CA. April 1992. *FASEB Journal*. 6:A1440.
38. *Zhang, J., T.J. Baker, M. De, T. Zhou, J.D. Mountz and **C.K. Edwards, III**. 1992. Tumor necrosis factor- α production and MHC class II expression by macrophages activated by *Staphylococcus enterotoxin B*. Presented at the Federation of American Society for Experimental Biology Annual Meeting. Anaheim, CA. April 1992. *FASEB Journal*. 6:A1969.
39. Baker, T.J., R.E. Long, M. De, L.M. Watts, J.D. Mountz and ***C.K. Edwards, III**. 1992. Histopathological assessment of orally administered Methotrexate in Lewis/N rat antigen-induced arthritis. Presented at the Federation of American Society for Experimental Biology Annual Meeting. Anaheim, CA. April 1992. *FASEB Journal*. 6:A1446.
40. *Mountz, J.D., T. Zhou, H. Bluethmann and **C.K. Edwards, III**. 1992. Autoreactive T-cells result from increased co-stimulatory signaling in TCR transgenic *lpr/lpr* mice. Presented at the Federation of American Society for Experimental Biology Annual Meeting. Anaheim, CA. April 1992. *FASEB Journal*. 6:A1987.
41. *Parmely, M.J., **C.K. Edwards, III**, D.R. Borcharding and D.C. Morrison. 1992. Effects of the carbocyclic nucleoside MDL 201,112 on cytokine production *in vitro* and *in vivo*. Presented at the 4th International TNF Congress. Koningshof, Veldhoven, the Netherlands. May 2-6, 1992. *European Cytokine Network*. 3:249.

42. *De, M. and **C.K. Edwards, III**. 1992. Superantigen-induced *in vitro* modulation of proinflammatory cytokine production and mRNA expression in macrophages. Presented at the International Society of Differentiation Annual Conference. Helsinki, Finland. July 19-23, 1992. Abstract 34.
43. *De, M., T.J. Baker, R.E. Long, K. W. Kelley and **C.K. Edwards, III**. 1992. Effects of aging on proinflammatory cytokine production and gene expression in antigen-induced arthritis. Presented at the Hans Selye Symposia on Neuroendocrinology and Stress. Advances in Psychoneuroimmunology. Satellite meeting of the 8th International Congress of Immunology. Budapest, Hungary. August 17-21, 1992. Page 16.
44. *De, M. and **C.K. Edwards, III**. 1992. Differential *in vitro* induction of proinflammatory cytokine gene expression and protein production by macrophages treated with bacterial superantigens. Presented at the American College of Rheumatology Annual Meeting. Atlanta, GA. October 10-15, 1992. *Arthritis and Rheumatism*. 35:S79.
45. De, M., T.J. Baker, R.E. Long, K.W. Kelley and ***C.K. Edwards, III**. 1992. Modulation of proinflammatory cytokine production and gene expression in young and aged Wistar Furth rats by antigen-induced arthritis. Presented at the American College of Rheumatology Annual Meeting. Atlanta, GA. October 10-15, 1992. *Arthritis and Rheumatism*. 35:S99.
46. De, M., T.J. Baker, R.E. Long, J.D. Mountz and ***C.K. Edwards, III**. 1992. Effect of cyclosporin a on proinflammatory cytokine gene expression and protein production in Lewis (LEW/N) rat antigen-induced arthritis. Presented at the American College of Rheumatology Annual Meeting. Atlanta, GA. October 10-15, 1992. *Arthritis and Rheumatism*. 35:S140.
47. *Mountz, J.D., T. Zhou, R.E. Long, H. Bluethmann, W.J. Koopman, J.M. Mountz and **C.K. Edwards, III**. 1992. Factors influencing development of T-cell dependent vs. non T-cell dependent arthritis. Presented at the American College of Rheumatology Annual Meeting. Atlanta, GA. October 10-15, 1992. *Arthritis and Rheumatism*. 35:S140.
48. ***Edwards, III, C.K.**, B.J. Hoepfer, D.R. Borcharding, M.J. Parmely, and T.L. Bowlin. 1993. Selective inhibition of human monocyte-macrophage derived TNF- α production, but not IL-1 β , by the carbocyclic nucleoside MDL 201,112. Presented at the Keystone Symposium "Cytokines and Cytokine Receptors". Keystone, CO. January 31-February 6, 1993. *Journal Cellular Biochemistry*. 17B: 104.
49. *Mistry, M., R.E. Long and **C.K. Edwards, III**. 1993. Effect of dietary salt modification on vascular smooth muscle proliferate response in rats. Presented at the FASEB Annual Meeting. New Orleans, LA. March 28-April 1, 1993. *FASEB Journal*. 7:A584.
50. ***Edwards, III, C.K.**, B.J. Hoepfer, D.R. Borcharding and T.L. Bowlin. 1993. The effects of a novel carbocyclic nucleoside in a murine model of endotoxin-induced septic shock. Presented at the American Association of Immunologists Annual Meeting. Denver, CO. May 21-25, 1993. *Journal of Immunology*. 150:296A.
51. *Hoepfer, B.J., D.R. Borcharding, T.L. Bowlin and ***C.K. Edwards, III**. 1993. A comparison of a novel carbocyclic nucleoside and pentoxifylline on human proinflammatory cytokine production *in vitro*. Presented at the American Association of Immunologists Annual Meeting. Denver, CO. May 21-25, 1993. *Journal of Immunology*. 150:296A.
52. Zhang, J., T. Zhou, J.D. Mountz and ***C.K. Edwards, III**. 1993. Defective *fas* antigen gene expression in peritoneal macrophages from aged MRL-*lpr/lpr* autoimmune mice correlates to enhanced TNF- α production. Presented at the American Association of Immunologists Annual Meeting. Denver, CO. May 21-25, 1993. *Journal of Immunology*. 150:85A.
53. *Ivanova-Bradshaw, M., M.S. Rutherford, **C.K. Edwards, III**, D.R. Borcharding, and L.B. Schook. 1993. Specific transcriptional inhibition of macrophage TNF- α gene expression using carbocyclic nucleosides. Presented at the American Association of Immunologists Annual Meeting. Denver, CO. May 21-25, 1993. *Journal of Immunology*. 150:212A.
54. ***Edwards, III, C.K.**, T. Zhou, J. Zhang, C.D. McWhinney, T.L. Bowlin and J.D. Mountz. 1993. Elevated proinflammatory cytokine production by macrophages obtained from aged MRL-*lpr/lpr* autoimmune mice correlates to defective *fas* antigen gene expression. Presented at the American College of Rheumatology Annual Meeting. San Antonio, TX. November 7-11, 1993. *Arthritis and Rheumatism*. 36:561. (Abstract 138).

55. *Parnely, M.J., W.W. Zhou, **C.K. Edwards, III**, D.R. Borcharding, S. Hao, E. Hausmann and D.C. Morrison. 1993. Endotoxin lethality in mice is prevented by a carbocyclic adenyly nucleoside. Presented at the 33rd ICACC Meeting. New Orleans, LA. October 1993. *Antimicrobial Agents & Chemotherapy*.
56. ***Edwards, III, C.K.**, M. Mistry, P. Hoffman, T.L. Bowlin and D.R. Borcharding. 1994. Down-regulation of serum tumor necrosis factor- α and enhanced protection against endotoxin-induced septic shock by the novel carbocyclic nucleoside analogue MDL 201,449. Presented at the American Association of Immunologists Annual Meeting. Anaheim, CA. April 24-28, 1994. *FASEB Journal*. 8:A22. (Abstract 1282).
57. *McWhinney, C.D., M. Bradshaw, D.R. Borcharding, L.B. Schook and **C.K. Edwards, III**. 1994. Transcriptional inhibition of endotoxin-induced tumor necrosis factor- α gene expression in murine J774.1 macrophages by the carbocyclic nucleoside analogue MDL 201,449. Presented at the American Association of Immunologists Annual Meeting. Anaheim, CA. April 24-28, 1994. *FASEB Journal*. 8:A779. (Abstract 4517).
58. Baker, T.J., *J.D. Mountz, R.E. Long, T. Zhou and **C.K. Edwards, III**. 1994. Increased susceptibility of *fas* mutant MRL- *lpr/lpr* mice to SEB-induced septic shock. Presented at the American Association of Immunologists Annual Meeting. Anaheim, CA. April 24-28, 1994. *FASEB Journal*. 8:A524. (Abstract 3036).
59. *Mountz, J., T. Zhou and **C.K. Edwards, III**. 1994. Correction of age-related T cell dysfunction in CD2-*fas* transgenic mice. Presented at the American Association of Immunologists Annual Meeting. Anaheim, CA. April 24-28, 1994. *FASEB Journal*. 8:A205. (Abstract 1183).
60. ***Edwards, III, C.K.**, M. Mistry, P. Hoffman, D.R. Borcharding and T.L. Bowlin. 1994. Efficacy of the novel carbocyclic nucleoside analogue MDL 201,449 in a neutropenic rat infection model of *Pseudomonas aeruginosa*-induced septic shock. Presented at the 5th International TNF Congress. Monterey, CA. May 30-June 3, 1994. *European Cytokine Network* 5:159. (Abstract 185).
61. *Bowlin, T.L., B. Hoepfer, A. Akeson, L. Mosher, D.R. Borcharding and **C.K. Edwards, III**. 1994. Inhibition of human macrophage and T-cell tumor necrosis factor- α production by a novel carbocyclic nucleoside analogue MDL 201,449. Presented at the 5th International TNF Congress. Monterey, CA. May 30-June 3, 1994. *European Cytokine Network* 5:158. (Abstract 138).
62. *McWhinney, C.D., M. Bradshaw, D.R. Borcharding, L.B. Schook, T.L. Bowlin and **C.K. Edwards, III**. 1994. Regulation of TNF- α gene expression in murine J774.1 macrophages by the carbocyclic nucleoside analogue MDL 201,449. Presented at the 5th International TNF Congress. Monterey, CA. May 30-June 3, 1994. *European Cytokine Network* 5:146. (Abstract 114).
63. *Cullen, C.M., P.F. Bonventre, H. Heeg, J.F. French and **C.K. Edwards, III**. 1994. A *fas* antigen mutation allows development of toxic shock syndrome toxin-1 (TSST-1)-induced lethal shock in V β 8.2 T-cell receptor transgenic mice. Presented at the 5th International TNF Congress. Monterey, CA. May 30-June 3, 1994. *European Cytokine Network* 5:160. (Abstract 148).
64. Riva, S., E. Biganzoli, **C.K. Edwards, III**, R. Williams, P. Ricciardi Castagnoli, M. Denaro and *M.L. Noll. 1994. Inhibition of the TNF- α production by different agents in LPS and LTA-induced macrophage cell clones. Presented at the 3rd International Conference on Cytokines. Florence, Italy. March 28-30, 1994.
65. ***Edwards, III, C.K.**, C.M. Cullen, P.F. Bonventre, H. Heeg, J.F. French, H. Bluethmann and J.D. Mountz. 1994. A *fas* antigen mutation allows development of toxic shock syndrome toxin-1 (TSST-1)-induced lethal shock in V β 8.2 T-cell receptor transgenic mice. Presented at the 58th Annual American College of Rheumatology Meeting, Minneapolis, MN. October 23-27, 1994. *Arthritis and Rheumatism* 37:S284 (Abstract 746).
66. Mountz, J.D., T.J. Baker, D.R. Borcharding, H. Bluethmann, T. Zhou and ***C.K. Edwards, III**. 1994. Increased susceptibility of *fas* mutant MRL-*lpr/lpr* mice to *Staphylococcal enterotoxin* β -induced septic shock. Presented at the 58th Annual American College of Rheumatology Meeting, Minneapolis, MN. October 23-27, 1994. *Arthritis and Rheumatism* 37: S389 (Abstract 1366).
67. *Shavit, Y., K.W. Kelley, **C.K. Edwards, III**, D.R. Borcharding, S. Arkin and R.W. Johnson. 1994. Inhibition of TNF- α synthesis in murine microglia by a novel carbocyclic nucleoside analogue.

- Presented at the 10th Annual Meeting on Neuroimmunomodulation. Orlando, FL. October 1994.
68. *Borcherding, D.R., **C.K. Edwards, III**, M.W. Dudley, J.M. Hitchcock, P.R. Kastner, C.D. McWhinney, M. De, B.T. Butler, K. Austin, N.L. Lentz, and N.P. Peet. 1994. New Selective adenosine receptor ligands. Presented at the "Drug-receptor mechanisms and lead discovery symposium", Great Lakes-Central American Chemical Society Regional Meeting, June 1-3, 1994, Ann Arbor, MI.
 69. ***Edwards, III, C.K.**, C.M. Cullen, P.F. Bonventre, H. Bluethmann and J.D. Mountz. 1995. Superantigen-induced lethal shock in V β 8.2 T-cell receptor transgenic mice is regulated by *fas*. Presented at the Keystone Symposium meeting "Apoptosis" (Programmed Cell Death). March 5-11, 1995, Tamarron, CO. *Journal of Cellular Biochemistry*. 1995. Supplement 19B: 280 (Abstract B8-201).
 70. ***Edwards, C.K., III**, P. Hoffman, M. Mistry, D.R. Borcherding, and T.L. Bowlin. 1995. Reduction of serum tumor necrosis factor- α (TNF- α) and enhanced protection in a neutropenic rat model of *Pseudomonas aeruginosa*-induced septic shock by the carbocyclic nucleoside MDL 201,449. Presented at the Experimental Biology 1995 Conference, April 10-15, 1995. *The FASEB Journal*. 9:A513 (Abstract 2972).
 71. ***Edwards, III, C.K.**, 1995. The efficacy of the novel carbocyclic nucleoside analogue MDL 201,449 in animal models of gram negative and gram-positive septic shock. Presented at the "Endotoxemia & Sepsis" Conference, June 19-21, 1995. Philadelphia, PA.
 72. ***Edwards, III, C.K.** 1995. Regulation of macrophage tumor necrosis factor- α gene expression by novel carbocyclic nucleosides. Presented at the "Role of Cytokines in Various Skin Diseases" Conference (Sponsored by Global Business Research), May 29-June 2, 1995. San Francisco, CA.
 73. *Mountz, J.D., T. Zhou, and **C.K. Edwards, III**. 1995. T cell function and life span analysis of CD2-*fas* transgenic mice. Presented at the Annual Meeting of the Gerontology Society of America (GSA), 1995.
 74. *Borcherding, D.R., T.L. Bowlin, N.P. Peet, M.W. Dudley, P.F. Hoffman, L.M. Watts, C.D. McWhinney and **C.K. Edwards, III**. 1995. MDL 201,449A: A nucleoside transcriptional regulator of tumor necrosis factor- α gene expression and its mechanism of action. Presented at the Gordon Conference "Nucleosides". Holderness, VT.
 75. ***Edwards, III, C.K.**, C.M. Cullen, P.F. Bonventre, H. Bluethmann, T. Zhou and J.D. Mountz. 1995. Superantigen-induced lethal shock in V β 8.2 T-cell receptor transgenic mice is regulated by a *fas* apoptosis receptor (*fasR*) mutation. Presented at the 9th International Congress of Immunology, July 23-29, 1995. 9th International Congress of Immunology (Abstract 817, p. 138).
 76. *Mountz, J.D., T. Zhou, M.D. Linnik, and **C.K. Edwards, III**. 1995. *Fas* mediates activation-induced apoptosis in macrophages and is compensated by TNF-TNFR in *lpr/lpr* mice. Presented at the 9th International Congress of Immunology, July 23-29, 1995. 9th International Congress of Immunology (Abstract 1671, p. 282).
 77. *Al-Humaidan, A., A.E. Elsofi, **C.K. Edwards, III**, and K. S.A. Khabar. 1995. Differential inhibition of monocyte prostaglandin E₂, TNF- α , and IL-8 secretion by the methylxanthine pentoxifylline (PTX), and the carbocyclic nucleoside analogue MDL 201,449A. Presented at the 9th International Congress of Immunology, July 23-29, 1995. 9th International Congress of Immunology (Abstract 633, p. 107).
 78. ***Edwards, III, C.K.**, T. Zhou, C. Cullen, P.F. Bonventre, D.B. Colagiovanni, H. Bluethmann, and J.D. Mountz. 1995. Increased susceptibility of *fas*-deficient and *fasL*-mutant mice to superantigen-induced lethal shock. Presented at the 59th American College of Rheumatology Meeting, October 22-26, 1995. San Francisco, CA. *Arthritis and Rheumatism*. 38:9 (Supplement) (Abstract 1329).
 79. *Grom, A.A., K. Murray, L. Luyrink, M. H. Passo, D. Witte, D.N. Glass, **C.K. Edwards, III**, and T. L. Bowlin. 1995. Up-regulated expression of TNF- α and its receptors in juvenile rheumatoid arthritis synovium. Presented at the 59th American College of Rheumatology Meeting, October 22-26, 1995. San Francisco, CA. *Arthritis and Rheumatism*. 38:9 (Supplement) (Abstract 935).
 80. *Bowlin, T.L., C. D. McWhinney, D.R. Borcherding, **C.K. Edwards, III**, P.F. Hoffman, L. Watts, and J.A. Wolos. 1995. Inhibition of NF- κ B nuclear translocation and TNF- α gene expression by a novel adenosine A₃ receptor agonist. Presented at the 59th American College of Rheumatology Meeting, October 22-26, 1995. San Francisco, CA. *Arthritis and Rheumatism*. 38:9 (Supplement) (Abstract 1485).

81. ***Edwards, III, C.K.** 1995. Recombinant human tumor necrosis factor-binding protein (TNF-bp): A novel, high-affinity soluble inhibitor of tumor necrosis factor- α . Presented at the Second Annual Inflammatory Cytokine Antagonists Conference (sponsored by Cambridge Healthcare Institute), November 13-15, 1995. Boston, MA.
82. *Colagiovanni, D.B., J. McCabe, R.J. Evans, A.M. Bendele, and **C.K. Edwards, III.** 1995. Recombinant human tumor necrosis factor-binding protein (TNF-bp) protects *fas* mutant MRL-*lpr/lpr* autoimmune mice against lipopolysaccharide/D-galactosamine-induced lethality. Presented at the Second Annual Inflammatory Cytokine Antagonists Conference (sponsored by Cambridge Healthcare Institute). November 22-23, 1995. Boston, MA.
83. ***Edwards, III, C.K.** 1996. The effects of recombinant human tumor necrosis factor-binding protein (TNF-bp) in animal models of acute and chronic inflammation. Presented at the Second Annual Sepsis/SIRS Conference, "Designing Better Drugs & Clinical Trials for Reducing Mortality to Patients and Suppliers", February 12-13, 1996. Washington, D.C.
84. Colagiovanni, D.B., J. McCabe, R.J. Evans, A.M. Bendele, and ***C.K. Edwards, III.** 1996. Tumor necrosis factor-binding protein (TNF-bp) protects *fas* mutant MRL-*lpr/lpr* mice against LPS or superantigen/D-galactosamine-induced lethality. Presented at the 6th International TNF Congress. May 8-12, 1996. Rhodes, Greece. *European Cytokine Network*. 7: 232 (Abstract 119).
85. *Mountz, J.D., T. Zhou, **C.K. Edwards, III,** and H. Bluethmann. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in *lpr* mice lacking tumor necrosis factor receptor I. Presented at the 6th International TNF Congress. May 8-12, 1996. Rhodes, Greece. *European Cytokine Network*. 7: 237 (Abstract 129).
86. Su, X., **C.K. Edwards, III,** T. Zhou, and *J.D. Mountz. 1996. Improved survival and decreased inflammatory lung and skin diseases in motheaten mice by treatment of TNF binding protein. Presented at the 6th International TNF Congress. May 8-12, 1996. Rhodes, Greece. *European Cytokine Network*. 7: 242 (Abstract 138).
87. Zhou, T., *J. D. Mountz, **C.K. Edwards, III,** and H. Bluethmann. 1996. *Fas* and tumor necrosis factor-receptor I-mediated activation-induced cell death of macrophages. Presented at the 6th International TNF Congress. May 8-12, 1996. Rhodes, Greece. *European Cytokine Network*. 7: 243 (Abstract 141).
88. *Khabar, K.S.A., A. Al-Humidan, M. Dzimiri, A. El-Sofi, S. Al-Sedairy, and **C.K. Edwards, III.** 1996. The novel carbocyclic nucleoside, MDL 201,449A is a TNF inhibitor with moderate down-modulatory immune functions. Presented at the American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, and the American Association of Immunologists Annual Meeting. June 2-6, 1996. New Orleans, LA. *FASEB. J.* 10: A1053 (Abstract 310).
89. **Edwards, III, C.K.,** *X. Su, T. Zhou and J.D. Mountz. 1996. Improved survival and decreased inflammatory lung and skin diseases in motheaten mice by treatment of TNF binding protein. Presented at the American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, and the American Association of Immunologists Annual Meeting. June 2-6, 1996. New Orleans, LA. *FASEB. J.* 10: A1330 (Abstract 1908).
90. *Evans, R.J., J. G. McCabe, A.M. Bendele, and **C.K. Edwards, III.** 1996. Efficacy of TNFbp in the streptococcal cell wall induced reactivation model of arthritis. Presented at the American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, and the American Association of Immunologists Annual Meeting. June 2-6, 1996. New Orleans, LA. *FASEB. J.* 10: A1331 (Abstract 1911).
91. *Zhou, T., **C.K. Edwards, III,** H. Bluethmann, and J.D. Mountz. 1996. *Fas* and tumor necrosis factor-I-mediated activation-induced cell death of macrophages. Presented at the American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, and the American Association of Immunologists Annual Meeting. June 2-6, 1996. New Orleans, LA. *FASEB. J.* 10: A1335 (Abstract 1935).
92. *Mountz, J.D., **C.K. Edwards, III,** H. Bluethmann, and T. Zhou. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in *lpr* mice lacking tumor necrosis factor receptor I.

- Presented at the American Society for Biochemistry and Molecular Biology, American Society for Investigative Pathology, and the American Association of Immunologists Annual Meeting. June 2-6, 1996. New Orleans, LA. *FASEB. J.* 10: A1440 (Abstract 2536).
93. ***Edwards, III, C.K.**, T. Zhou, J.G. McCabe, R.E. Long, D.R. Borcharding, T.L. Bowlin, H. Bluethmann, and J.D. Mountz. 1996. Inhibition of inflammatory arthritis in *fas* mutant aged MRL-*lpr/lpr* mice by TNF- α antagonists. Presented at the First International Conference on Immunology and Aging. Natcher Conference Center, National Institutes of Health, Bethesda, MD. June 16-19, 1996. *NIH Press: Aging and the Immune System Conference Proceedings.* 1:33 (Abstract S-5).
 94. *Burger, D., G. Kieft, J. Seely, J.M. Dayer, and **C.K. Edwards, III.** 1996. Inhibition of proinflammatory factor production by fibroblasts-like cells with TNF-binding protein (TNF-bp). Presented at the First Joint Meeting of the International Cytokine Society (ICS) and the International Society for Interferon and Cytokine Research (ISCIR). October 6-10, 1996. Geneva, Switzerland. *European Cytokine Network.* 7: 561 (Abstract 387).
 95. *Roubenoff, R., **C.K. Edwards, III,** J.J. Kehayias, D.E. Smith, L.W. Abad, A.M. Bendele, C. Bucher, M. Nicholson, J. Frazier, and C.A. Dinarello. 1996. TNF- α and leptin in adjuvant arthritis (AA): Implications for inflammatory cachexia. Presented at the 60th National Scientific Meeting of the American College of Rheumatology. October 18-22, 1996. Orlando, FL. *Arthritis and Rheumatism* 39: S77 (Abstract 302).
 96. Su, X, **C.K. Edwards, III,** *J.D. Mountz, and T. Zhou. 1996. Greatly decreased inflammatory disease in HCP-deficient motheaten mice treated with TNF binding protein. Presented at the 60th National Scientific Meeting of the American College of Rheumatology. October 18-22, 1996. Orlando, FL. *Arthritis and Rheumatism* 39: S108 (Abstract 488).
 97. Zhou, T., **C.K. Edwards, III,** H. Bluethmann, and *J.D. Mountz. 1996. *Fas* and tumor necrosis factor-receptor I-mediated activation-induced cell death of macrophages. Presented at the 60th National Scientific Meeting of the American College of Rheumatology. October 18-22, 1996. Orlando, FL. *Arthritis and Rheumatism* 39: S120 (Abstract 560).
 98. *Mountz, J.D., **C.K. Edwards, III,** H. Bluethmann, and T. Zhou. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in *lpr* mice lacking tumor necrosis factor receptor I. Presented at the 60th National Scientific Meeting of the American College of Rheumatology. October 18-22, 1996. Orlando, FL. *Arthritis and Rheumatism* 39: S161 (Abstract 806).
 99. Evans, R.J., A.M. Bendele, G.L. Kieft, T.J. McAbee, and ***C.K. Edwards, III.** 1996. Efficacy of tumor necrosis factor binding protein (TNF-bp) in the streptococcal cell wall-induced reactivation model of arthritis. Presented at the 60th National Scientific Meeting of the American College of Rheumatology. October 18-22, 1996. Orlando, FL. *Arthritis and Rheumatism* 39: S284 (Abstract 1540).
 100. *Bowlin, T.L., McWhinney, C.D., D.R. Borcharding, and **C.K. Edwards, III.** 1996. Regulation of TNF-alpha gene expression by the adenosine A₃ receptor. Purines '96. Academic Press. New York, NY. Page 145.
 101. *Ksontini, R., D. Colagiovanni, J.N. Vauthey, C.C. Solorzano, E.K. Abdalla, M.D., Josephs, A.K. Moshvedi, D.L. Lazarus, G.Kieft, S.L.D MacKay, E.M. Copeland, III, **C.K. Edwards, III,** and L.L. Moldawer. 1997. Involvement of *fas* and *fas* ligand in ConA induced hepatitis. Presented at the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis-Mechanism and Therapeutic Approaches. March 4-8, 1997, Munich, Germany. *Shock.* 7:59 (Abstract 233).
 102. Colagiovanni, D.B., R. Ksontini, R.J. Evans, G. Kieft, T. Kohno, C. Elias, J. St. Clair, T. Zhou, J.D. Mountz, L.L. Moldawer, and ***C.K. Edwards, III.** 1997. Involvement of *fas* and *fasL* in LPS or *S. enterotoxin* B/D-galactosamine-induced lethality using *fas* mutant MRL-*lpr/lpr* and MRL-+/+ mice. Presented at the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis-Mechanism and Therapeutic Approaches. March 4-8, 1997, Munich, Germany. *Shock.* 7:17 (Abstract 66).
 103. *Clare-Salzler, M.J., C.C. Solorzano, M.D. Josephs, **C.K. Edwards, III,** S.L.D. MacKay, and L.L. Moldawer. 1997. Tumor necrosis factor binding protein (TNF-bp) reduces neutropenia and loss of *fas* positive peripheral blood leukocytes in septic baboons. Presented at the 4th International Congress on

- the Immune Consequences of Trauma, Shock and Sepsis-Mechanism and Therapeutic Approaches. March 4-8, 1997, Munich, Germany. *Shock*. 7:117 (Abstract 463).
104. *Moshyedi, A.K., R. Ksontini, M.D. Josephs, E.K. Abdalla, **C.K. Edwards, III**, T. Auffenberg, S.L.D. MacKay, E.M. Copeland, III, and L.L. Moldawer. 1997. Failure of TNF- α to regulate serum leptin levels in sepsis. Presented at the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis-Mechanism and Therapeutic Approaches. March 4-8, 1997, Munich, Germany. *Shock*. 7:98 (Abstract 386).
 105. Zhou, T., **C.K. Edwards, III**, R.J. Evans, H. Bluethmann, and *J.D. Mountz. 1997. Macrophage activation-induced cell death is mediated by *fas* ligand and TNF- α Presented at the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis-Mechanism and Therapeutic Approaches. March 4-8, 1997, Munich, Germany. *Shock*. 7:116 (Abstract 458).
 106. *Borcherding, D.R., C.D. McWhinney, N.P. Peet, and **C.K. Edwards, III**. 1997. Adenosine agonists inhibit the *in vitro* and *in vivo* production of TNF- α through the A3 receptor. Presented at the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis-Mechanism and Therapeutic Approaches. March 4-8, 1997, Munich, Germany. *Shock*. 7:77 (Abstract 30).
 107. ***Edwards, III, C.K.** 1997. Recombinant human tumor necrosis factor binding protein (TNFbp): A novel high-affinity soluble inhibitor of tumor necrosis factor- α . Presented at the 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis-Mechanism and Therapeutic Approaches. March 4-8, 1997, Munich, Germany. *Shock*. 7:75 (Abstract 297).
 108. ***Edwards, III, C.K.** 1997. Involvement of TNF- α and *fasL* in inflammatory processes: Therapeutic effects using tumor necrosis factor binding protein and a *fas* fusion protein. Presented at "Immunopathology of mucous membranes and exocrine glands". May 13-16, 1997. Bergen, Norway. *Scandinavian Journal of Rheumatology*. 45: 560 (Abstract 15).
 109. Mountz, J.D., T. Zhou, **C.K. Edwards, III**. 1997. Chronic inflammation results from defective *fas* and TNF-RI apoptosis. Presented at "Immunopathology of mucous membranes and exocrine glands". May 13-16, 1997. Bergen, Norway. *Scandinavian Journal of Rheumatology*. 45: 560 (Abstract 14).
 110. *Ksontini, R., C.L. Tannahill, D.B. Colagiovanni, **C.K. Edwards, III**, Z. Abouhamze, J. -N. Vauthey, E.M. Copeland, III, L.L. Moldawer and S.L.D MacKay. 1997. Activation of the *fas/fas* ligand pathway induces a TNF- α response that attenuates *fasL* mediated liver injury. Presented at the Critical Care Surgery Conference. June 1997. Washington, D.C.
 111. *Fleck, M., J.D. Mountz, T. Zhou, W. Wintersberger, **C.K. Edwards, III**, and E.R. Kern. 1997. The role of the apoptosis-mediating molecules *fas* and TNF-receptor-I in herpesvirus infections in mice. Presented at the 22nd International Herpesvirus Workshop. August 2-8, 1997. La Jolla, CA.
 112. *Zhang, H-G, T. Zhou, D.T. Curiel, **C.K. Edwards, III**, and J.D. Mountz. 1997. Use of soluble TNF-receptor as a modulator of the inflammatory response to adenovirus vector antigens. Presented at the 61st American College of Rheumatology National Scientific Meeting. November 8-12, 1997. Washington, D.C. *Arthritis and Rheumatism* 40:S220 (Abstract 1138).
 113. *Wintersberger, W., M. Fleck, **C. K. Edwards, III**, and J.D. Mountz. 1997. RA synovial T cells exhibit susceptibility to *fas* apoptosis which is inhibited by TNF. Presented at the 61st American College of Rheumatology National Scientific Meeting. November 8-12, 1997. Washington, D.C. *Arthritis and Rheumatism* 40:S120 (Abstract 535).
 114. *Zhou, T., H-D. Zhang, **C.K. Edwards, III**, H. Bluethmann, and J.D. Mountz. 1997. Induction of specific T cell tolerance by *fas* ligand expressing antigen-presenting cells. Presented at the 61st American College of Rheumatology National Scientific Meeting. November 8-12, 1997. Washington, D.C. *Arthritis and Rheumatism* 40: S 117 (Abstract 517).
 115. *Fleck, M., E.R. Kern, T. Zhou, W. Wintersberger, **C. K. Edwards, III**, and J.D. Mountz. 1997. A new model for Sjogren's syndrome and autoimmune disease in *lpr* mice induced by murine cytomegalovirus infection. Presented at the 61st American College of Rheumatology National Scientific Meeting. November 8-12, 1997. Washington, D.C. *Arthritis and Rheumatism* 40:S225 (Abstract 1165).
 116. Colagiovanni, D., R. Ksontini, R. Evans, G. Kieft, T. Kohno, J. Spellberg, T. Zhou, J. D. Mountz, S. Wooden, U. Selvanayagam, S. Hu, M. Clare-Salzler, H. Bluethmann, L. Moldawer, and ***C. K.**

- Edwards, III.** 1997. Involvement of *fas* ligand (*fasL*) in LPS-induced septic shock using *fas*-deficient MRL-*lpr/lpr* mice: Concomitant proinflammatory effects with TNF- α . Presented at the 5th Annual Conference International Cytokine Society. November 9-13, 1997. Lake Tahoe, NV. *Cytokine* 9: 913 (Abstract 94).
117. ***Edwards, C.K., III**, G. Henry, J. Seely, S.W. Martin, C. Yee, A.M. Bendele, T. Kohno, M.E. Cosenza, S. Lyons, and D. McCabe. 1998. A phase I/II study to evaluate the safety, immunogenicity, pharmacokinetics and potential efficacy of human tumor necrosis factor binding protein PEGylated dimer (TNFbp) in patients with active rheumatoid arthritis. Presented at the Keystone Symposium "Pathogenesis of Rheumatoid Arthritis: Implications for Future Therapy. January 23-29, 1998. Tamarron, CO. *Cellular and Molecular Biology*. P. 38 (Abstract 404).
118. *Rosenberg, J.J., G.C. Gaines, J. Rose, M. Clare-Salzler, S.L.D. MacKay, **C.K. Edwards, III**, E.M. Copeland, III, and L.L. Moldawer. 1998. Apoptotic organ injury in a primate model of bacteremic shock. Presented at the Surgical Infection Society Annual Meeting. April 1998. Washington, D.C.
119. *Carney, D., C. Finck, W. Marx, C. Lotz, L. Gatto, A. Picone, C. Lopez, A. Paskanik, K. Snyder, and **C.K. Edwards, III**. 1998. Prevention of endotoxin induced neutropenia with soluble tumor necrosis factor receptor (TNFbp). Presented at the Annual Meeting of Critical Care Medicine. April 1998. Washington, D.C.
120. *Carney, D., C. Finck, W. Marx, C. Lutz, L. Gatto, A. Picone, C. Lopez, A. Paskanik, K. Snyder, and **C. K. Edwards, III**. 1998. Prevention of endotoxin induced neutropenia with soluble tumor necrosis factor receptor (TNFbp). Presented at the XIII World Congress of Cardiology. April 1998. Rio de Janeiro, Brazil.
121. *Josephs, M., M. Clare-Salzler, T. Kohno, **C.K. Edwards, III**, and L.L. Moldawer. 1998. TNF dependent, leukocyte *fas* expression in lethal baboon bacteremia. Presented at Experimental Biology 98: American Association of Immunologists (AAI). April 18-2, 1998. San Francisco, CA.
122. *Solorzano, C.C., T. Kohno, S.W. Martin, L.L. Moldawer, and **C.K. Edwards, III**. 1998. Pharmacokinetics, immunogenicity and efficacy of dimeric, PEGylated TNF receptor binding proteins in the healthy and bacteremic baboon. Presented at Experimental Biology 98: American Association of Immunologists (AAI). April 18-2, 1998. San Francisco, CA.
123. *Moshlyedi, A., M. Clare-Salzler, S.W. Martin, T. Kohno, L.L. Moldawer, and **C.K. Edwards, III**. 1998. Novel monomeric and dimeric TNF binding protein (TNFbp) constructs with reduced immunogenicity in the baboon. Presented at Experimental Biology 98: American Association of Immunologists (AAI). April 18-2, 1998. San Francisco, CA.
124. *Simon, H., C. Lopez, D. Carney, C. Finck, C. Lutz, W. Marx, A. Picone, L. Gatto, A. Paskanik, K. Snyder, **C. K. Edwards, III**, and G. Nieman. 1998. Soluble tumor necrosis factor receptor (TNFbp) prevents gastric but not ileal hypoperfusion in acute endotoxemia. Presented at the Twenty First Annual Conferences on Shock. June 14-17, 1998. San Antonio, Texas.
125. *Marx, W., D. Carney, C. Finck, C. Lutz, A. Picone, L. Gatto, A. Paskanik, K. Snyder, **C. K. Edwards, III**, and G. Nieman. 1998. Prophylactic and therapeutic treatment of the adult respiratory distress syndrome (ARDS) with soluble tumor necrosis factor receptor (TNFbp). Presented at the Twenty First Annual Conferences on Shock. June 14-17, 1998. San Antonio, Texas.
126. *Bendele, A.M., J. McComb, T. Gould, L. Chilpala, J. Frazier, D. Colagiovanni, and **C.K. Edwards, III**. 1998. Comparative efficacy of sTNF-RI, a novel monomeric, recombinant soluble TNF Type I receptor, to dimeric sTNF-RI and sTNF-RII IgG₁ Fc fusion proteins. Presented at the 7th International TNF Congress. May 17-21, 1998. Hyannis, Massachusetts. *European Cytokine Network*. 1998. 18: A-89 (Abstract 5.06).
127. ***Edwards, III**, C.K., G. Henry, J. Seely, S.M. Martin, A.M. Bendele, T. Kohno, M.E. Cosenza, S. Lyons and D. McCabe. 1998. A phase I/II study to evaluate the safety, immunogenicity, pharmacokinetics and potential efficacy of intravenous recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer (TNFbp) in patients with active rheumatoid arthritis. Presented at the 7th International TNF Congress. May 17-21, 1998. Hyannis, Massachusetts. *European Cytokine Network*. 1998. 18: A126 (Abstract 6.11).
128. ***Edwards, III, C.K.**, G. Kieft, C. Elias, T. Kohno, L.L. Moldawer, J.D. Mountz, and T. Zhou. 1998.

- Fas* ligand (*fasL*) and TNF- α play concomitant roles in mediating apoptosis of macrophages. Presented at the 7th International TNF Congress. May 17-21, 1998. Hyannis, Massachusetts. *European Cytokine Network*. 1998. 18: A-67 (Abstract 4.09).
129. *Rosenberg, J.J., G. Gaines, S. Martin, T. Kohno, **C.K. Edwards, III**, and L.L. Moldawer. 1998. Immunogenicity and therapeutic efficacy of novel soluble TNF receptor constructs in the baboon. Presented at the 7th International TNF Congress. May 17-21, 1998. Hyannis, Massachusetts. *European Cytokine Network*. 1998. 18: A-129 (Abstract 6.24).
 130. *Kohno, T., S. Baker, J. Frazier, G. Kieft, G. Brown, D. Schriefer, J. Seely, H. Gaylord, A. Amicone, M.E. Cosenza, W. Boyle, and **C. K. Edwards, III**. 1998. Assessment of the major antigenic epitopes of the recombinant human soluble p55 TNF type I receptor: Design of a novel monomeric non-immunogenic analog, sTNF-RI. Presented at the 7th International TNF Congress. May 17-21, 1998. Hyannis, Massachusetts. *European Cytokine Network*. 1998. 18: A126 (Abstract 6.17).
 131. *Zinn, K.R., **C. K. Edwards, III**, C.A. Smyth, H.G. Liu, J.D. Mountz, and J.M. Mountz. 1998. *In vivo* imaging of TNF- α using a Tc-99m-labeled soluble TNF- α receptor in an adjuvant-induced arthritis model. Proceedings of the 45th Annual Meeting of Society of Nuclear Medicine. *Journal of Nuclear Medicine*. 1998. 39: 225P (Abstract 996).
 132. *Gaines, G.C., M. Nowak, J.J. Rosenberg, K. Fukuzuka, **C.K. Edwards, III**, L.L. Moldawer, S. L.D. MacKay, and E.M. Copeland, III. 1998. Both membrane-associated and soluble tumor necrosis factor- α (TNF- α) induce hepatocyte apoptosis exclusively through p55 TNF receptor signaling. Presented at the Eastern Florida Surgical Society Regional Meeting. October 1998.
 133. ***Edwards, III, C.K.**, A. Garrison, L. Reznikov, G. Fantuzzi, A.M. Bendele, E. Chlipala, J. Frazier, T. Zhou, J.D. Mountz, and C.A. Dinarello. 1998. Induction of chronic synovitis and generalized autoimmune disease in tumor necrosis factor- α deficient mice treated with viable *Mycoplasma pulmonis*. Presented at the 62nd American College of Rheumatology National Meeting. San Diego, CA. November 8-12, 1998. *Arthritis & Rheumatism*. 41: S213 (abstract 1085).
 134. *Martin, S., J. Frazier, J. Seely, A. Amicone, M.E. Cosenza, J.J. Rosenberg, T. Kohno, L.L. Moldawer, and **C.K. Edwards, III**. 1998. A genetically modified tumor necrosis factor receptor I (sTNF-RI) that does not elicit antibody response in primates. Presented at the 62nd American College of Rheumatology National Meeting. San Diego, CA. November 8-12, 1998. *Arthritis & Rheumatism*. 41: S58 (abstract 151).
 135. *McCabe, D.M., L. Moreland, J. Caldwell, M. Sack, M. Weisman, and **C.K. Edwards, III**. 1998. A phase I/II study to evaluate the safety, immunogenicity, pharmacokinetics and potential efficacy of IV rHuTNF binding protein PEGylated dimer (TNFbp) in patients with active RA. Presented at the 62nd American College of Rheumatology National Meeting. San Diego, CA. November 8-12, 1998. *Arthritis & Rheumatism*. 41: S58 (abstract 154).
 136. ***Edwards, III, C.K.**, J. Frazier, J. Seely, H. Gaylord, S. Martin, A. Amicone, M.E. Cosenza, W. Boyle, and T. Kohno. 1998. Assessment of the major antigenic epitopes of the recombinant human soluble p55 TNF Type I receptor: design of a novel monomeric non-immunogenic analog, sTNF-RI. Presented at the 62nd American College of Rheumatology National Meeting. San Diego, CA. November 8-12, 1998. *Arthritis & Rheumatism*. 41: S58 (abstract 153).
 137. *Song, G.G.S., **C.K. Edwards, III**, T. Zhou, and J.D. Mountz. 1998. Decreased lymphoproliferative disease and autoantibody production in B6-TNF-RI^{0/0}-*gld/gld* mice. Presented at the 62nd American College of Rheumatology National Meeting. San Diego, CA. November 8-12, 1998. *Arthritis & Rheumatism*. 41: S140 (abstract 646).
 138. *Zhang, H. -G., T. Zhou, **C.K. Edwards, III**, W. R. Rich, and J.D. Mountz. 1998. Adeno-associated virus (AAV) production of sTNF-RI and IL-1RA neutralizes TNF- α and IL-1 and reduces collagen-induced arthritis. Presented at the 62nd American College of Rheumatology National Meeting. San Diego, CA. November 8-12, 1998. *Arthritis & Rheumatism*. 41: S384 (abstract 384).
 139. *Zinn, K.R., T.R. Chaudhuri, **C.K. Edwards, III**, H.G. Liu, J.D. Mountz, and J.M. Mountz. 1998. A novel Tc-99m-labeled soluble receptor for *in vivo* imaging of TNF- α expression in arthritis animal models. Presented at the 62nd American College of Rheumatology National Meeting. San Diego, CA. November 8-12, 1998. *Arthritis & Rheumatism*. 41: S213 (abstract 1081).

140. *Zinn, K.R., T.R. Chaudhuri, **C.K. Edwards, III**, H.G. Liu, J. M. Mountz, and J.D. Mountz. 1998. Imaging TNF- α expression in adjuvant arthritis. *Presented at* the Inflammation Research Association Ninth International Conference. Hershey, PA. November 1-5, 1998.
141. *Fukuzuka, K., R. Minter, J. Rectenwald, D. Mozingo, **C.K. Edwards, III**, L. Moldawer. 1999. Organ apoptosis is dependent on glucocorticoids but not FasL early after burn injury. *Presented at* the Fourth International Shock Congress. Philadelphia, PA. June 12-16, 1999.
142. *Smith, D.E., J. Morrison, L.W. Abad, **C.K. Edwards, III**, R. Roubenoff. 1999. Modulation of inflammatory cachexia in adjuvant arthritis: effect of sex, age, and cytokine blockade. *Presented at* the Canadian Association of Laboratory Animal Science Meeting. Toronto. July 1999.
143. ***Edwards, III, C.K.** 1999. The effects of Interleukin-1 receptor antagonist (IL-1ra) and soluble tumor necrosis factor receptor type I (sTNF-RI) in inflammatory diseases. *Presented at* the First Annual Meeting for TNF- α in Therapeutic Strategies for Clinical Medicine. Half Moon Bay, Jamaica. March 25-30, 1999.
144. *Bendele AM, ES Chlipala, WR Rich, and **CK Edwards III**. Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-1ra) and PEGylated recombinant human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in animal models of rheumatoid arthritis. *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*. 42: S171 (Abstract 602).
145. *Tornwald J, H Fox, **CK Edwards, III**, and RI Fox. Treatment with PEGylated recombinant methionyl human soluble tumor necrosis factor-type I receptor (PEG sTNF-RI) prevents development of Sjogren's syndrome and diabetes in the NOD mouse model. *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*. 42: S403 (Abstract 1992).
146. *Caldwell JR, Davis MW, Jelaca-Maxwell K, Wang A, Wason S, Chase W, Miskin BM, **Edwards III CK**. A phase 1 study of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI [p55]) in subjects with rheumatoid arthritis (RA). *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*. 42: S236 (Abstract 993).
147. *Davis MW, Frazier JL, Martin SW, **Edwards III CK**. Non-immunogenicity of a PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI [p55]). *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*. 42: S77 (Abstract 37).
148. ***Edwards III CK**, Chlipala ES, Dinarello CA, Reznikov LL, Moldawer LL, Bendele AM. Clinical and histopathologic characterization of arthritis in male and female tumor necrosis factor- α knockout (TNF- $\alpha^{-/-}$) and membrane-bound TNF- α transgenic (TNF- α^{TgA86}) mice injected with *Mycoplasma Pulmonis* or *Mycoplasma Arthritidis*. *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*. 42: S120 (Abstract 296).
149. *Martin SW, Sommers JS, Macri MJ, Newmark RD, Jelaca-Maxwell K, Turner SA, Frazier JL, Young JK, **Edwards III CK**, Davis MW. The pharmacokinetics of subcutaneous injections of PEGylated recombinant methionyl human soluble tumor necrosis factor-type I receptor (PEG sTNF-RI) in subjects with active rheumatoid arthritis. *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*. 42: S79 (Abstract 50).
150. *Hsu HC, Z Wang, P Yang, T Zhou, **C.K. Edwards, III**, and J.D. Mountz. Age-related autoantibodies and autoimmune disease in vivo results from defective apoptosis. *Presented at* the ACR 63rd Annual Scientific Meeting, Boston, MA 1999. *Arthritis & Rheumatism*. 42: S261 (Abstract 1142).
151. *Frishman JI, **Edwards, III CK**, Dinarello CA. Differences in the ability of soluble p75 and p55 TNF receptors to inhibit spontaneous and TNF-inducible IL-8 production in whole blood cultures. *Presented at* the International Cytokine Society Meeting, Hilton Head, SC 1999. *Cytokine*. 11:920 (Abstract 34).
152. *Brandhuber, B.J., D.J. Dripps, **C.K. Edwards, III**, and G.P.A. Vigers. Crystal structure of an IL-1 receptor antagonist peptide complexed with IL-1 receptor type I. *Presented at* the ASBMB Annual Meeting, Denver, CO June 2000. *Journal of Biochemistry and Molecular Biology*. Abstract 483.
153. Bendele, A.M., E.S. Chlipala, W.R. Rich, and ***C.K. Edwards, III**. Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-1ra) and PEGylated recombinant human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in animal models of rheumatoid arthritis.

- Presented at* the Annual European Congress of Rheumatology (EULAR), Nice, France June 21-24, 2000. *Annals of Rheumatic Diseases*. 59: 147 (Abstract 350).
154. Caldwell, J.R., *M.W. Davis, K. Jelaca-Maxwell, A. Wang, S. Wason, W. Chase, B.M. Miskin, and **C.K. Edwards, III**. A phase 1 study of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI [p55]) in subjects with rheumatoid arthritis (RA). *Presented at* the Annual European Congress of Rheumatology (EULAR), Nice, France June 21-24, 2000. *Annals of Rheumatic Diseases*. 59: 157 (Abstract 390).
 155. *Davis, M.W., J.L. Frazier, S.W. Martin, and **C.K. Edwards, III**. Non-immunogenicity of a PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI [p55]). *Presented at* the Annual European Congress of Rheumatology (EULAR), Nice, France June 21-24, 2000. *Annals of Rheumatic Diseases*. 59: 157 (Abstract 391).
 156. Frishman, J.I., ***C.K. Edwards, III**, M.G. Sonnenberg, H. Kohno, A.M. Cohen and C.A. Dinarello. TNF- α induced IL-8 in whole blood culture discriminates neutralization by p55 and p75 soluble TNF receptors. *Presented at* the Annual European Congress of Rheumatology (EULAR), Nice, France June 21-24, 2000. *Annals of Rheumatic Diseases*. 59: 192 (Abstract 548).
 157. *Hyka, N., J. -M. Dayer, C. Modoux, T. Kohno, **C.K. Edwards, III**, P. Roux Lombard, and D. Burger. A novel anti-inflammatory function for apolipoprotein A-I: Blockade of interleukin-1 β and tumor necrosis factor- α production by human monocytes upon contact-mediated activation by stimulated T lymphocytes. *Presented at* the LSO Meeting, Geneva, Switzerland, September 2000.
 158. Frishman, J.I., ***C.K. Edwards, III**, M.G. Sonnenberg, T. Kohno, A.M. Cohen, and C. A. Dinarello. Tumor necrosis factor- α -induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 tumor necrosis factor soluble receptors. *Presented at* the American College of Rheumatology 64th Annual Meeting, Philadelphia, PA, October 20-24, 2000. *Arthritis and Rheumatism*. 43: S80 (Abstract 79).
 159. *T. Kohno, **C.K. Edwards, III**, and M.G. Sonnenberg. BiaCore analysis of receptor binding with covalently and non-covalently associated TNF- α . *Presented at* the American College of Rheumatology 64th Annual Meeting, Philadelphia, PA, October 20-24, 2000. *Arthritis and Rheumatism*. 43: S79 (Abstract 78).
 160. *A. M. Bendele, C.A. Dinarello, E. Chlipala, and **C.K. Edwards, III**. Effects of PEG sTNF-RI, IL-1ra, or the combination in TNF- α knockout mice expressing a mutant form of murine transmembrane TNF- α . *Presented at* the American College of Rheumatology 64th Annual Meeting, Philadelphia, PA, October 20-24, 2000. *Arthritis and Rheumatism*. 43: S230 (Abstract 983).
 161. *Dayer, J.M., N. Hyka, C. Modoux, T. Kohno, **C.K. Edwards, III**, P. Roux-Lombard, and D. Burger. Apolipoprotein A-I inhibits IL-1 β and TNF- α production by blocking contact-mediated activation of monocytes by T lymphocytes. *Presented at* the American College of Rheumatology 64th Annual Meeting, Philadelphia, PA, October 20-24, 2000. *Arthritis and Rheumatism*. 43: S354 (Abstract 1726).
 162. ***C.K. Edwards, III**, M.G. Sonnenberg, and T. Kohno. BiaCore analysis of receptor binding with covalently and non-covalently associated TNF- α . *Presented at* the Third Joint Meeting of the International Cytokine Society (ICS) and the International Society for Interferon and Cytokine Research (ISICR). Amsterdam, the Netherlands, November 5-9, 2000. *European Cytokine Network*.
 163. Hyka, N., J.M. Dayer, C. Modoux, T. Kohno, **C.K. Edwards, III**, P. Roux-Lombard, and *D. Burger. Apolipoprotein A-I inhibits IL-1 β and TNF- α production by blocking contact-mediated activation of monocytes by T lymphocytes. *Presented at* the Keystone Symposium "Interfaces Between Innate and Adaptive Immunity", Keystone, CO, January 22-27, 2001.
 164. Ara, G., D. Fong, A. Baher, N. Storm, S. Khare, K. Miner, S. Eastman, M. Coccia, J. Pistillo, V. Lawless, D. Brankow, R. Deshpande, S. Hu, A. Moore, C. Baikalov, R. Camacho, E. Brisna, A. Winters, A. Tafuri, A. Shahihan, T.W. Mak, H. Nguyen, P. DeRose, W. Xu, S. Sander, D. Hill, D. Danilenko, G. Chow, S. Scully, D. Yanagihara, P. Campbell, D. Chang, S. McCabe, S. Steavenson, S. Hara, J. Bunch, T. Horan, H. Goldman, H. Kohno, M. Zhang, J.S. Whoriskey, K. Gaida, **C.K. Edwards, III**, and *S.K. Yoshinaga. T-Cell co-stimulation through the ICOS/B7RP-1 pathway. *Presented at* the 9th Annual International Symposium on Recent Advances in Hematopoietic Stemcell Transplantation, San Diego, CA, March 29-31, 2001.

165. *Atkinson, J.E., R.V. House, P.S. Cranmer, A. Coluci, H. Davis, **C.K. Edwards, III**, and D.M. Miller. Effect of Anakinra (IL-1Ra) and soluble tumor necrosis factor receptor type I (sTNF-RI) on cellular immune function in rats. Presented at the Society of Toxicology Annual Meeting. San Francisco, CA, March 28, 2001. *Journal of Toxicology*.
166. *Lundberg, P., P.V. Welander, **C.K. Edwards, III**, L. Moldawer, and E.M. Cantin. A novel locus on distal mouse chromosome 6 determines resistance to HSV-1. Presented at the Gordon Conference "Viruses and Cells", Tilton, NH. May 24-29, 2001.
167. *Schiff, M., R. Fleischmann, E. Kopp, M. Macri, T. Joh, **C.K. Edwards, III**, M.W. Davis, and the PEG sTNF-RI Study Group. The efficacy of PEGylated recombinant methionyl human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) dosed once weekly in a randomized, placebo-controlled double blind, clinical study of patients with rheumatoid arthritis (RA). Presented at the EULAR International Meeting, Prague, Czechoslovakia, June 15-19, 2001. *Annals of Rheumatic Diseases*. Volume 60:2001
168. *Schiff, M., R. Fleischmann, E. Kopp, M. Macri, T. Joh, **C.K. Edwards, III**, M.W. Davis, and the PEG sTNF-RI Study Group. The safety of PEGylated recombinant methionyl human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in a randomized, placebo-controlled, double blind, clinical study of patients with rheumatoid arthritis (RA). Presented at the EULAR International Meeting, Prague, Czechoslovakia, June 15-19, 2001. *Annals of Rheumatic Diseases*. Volume 60:2001.
169. ***C.K. Edwards, III**. Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist (IL-1ra) and PEGylated recombinant human soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in rheumatoid arthritis Presented at the 11th International Congress of Immunology. Stockholm, Sweden, July 22-28, 2001. *Scandinavian Journal of Immunology*.
170. *P. Zacone, F. Nicoletti, Z. Fehervari, **C. K. Edwards, III**, and A. Cooke. Autoimmune thyroid disease induced by thyroglobulin and LPS is inhibited by sTNF-RI. Presented at the 11th International Congress of Immunology. Stockholm, Sweden, July 22-28, 2001. *Scandinavian Journal of Immunology*.54: Supplement 1, July/August 2002. p.65 (Abstract 670).
171. *I. Goncharov, **C.K. Edwards, III**, S.H. Kim, M.J. Gresser, C.A. Dinarello, and L.L. Reznikov. Differences between the ability of TNF soluble p75 receptor: Fc and p55 receptor: PEG to neutralize TNF alpha-induced IL-8 in human blood cultures at the level of steady state mRNA. Presented at the International Cytokine Meeting. Honolulu, Hawaii, November 10-15, 2001. *J. Leukocyte Biology*.
172. ***C.K. Edwards, III**, R.F. Baltera, D.M. Miller, D. Rich, M.J. Gresser, C.A. Dinarello, V.A. Marsh, K.A. Storm, D.B. Trollinger, D.M. Bankaitis-Davis, and M.J. Bevilacqua. Inhibition of proinflammatory gene expression by soluble TNF receptors in human whole blood cultures: Marked contrast between TNF p55 receptor (PEG sTNF-RI) and TNF p75 receptor (Etanercept). Presented at the 65th Annual Scientific Meeting of the American College of Rheumatology. San Francisco, CA, November 11-16, 2001. *Arthritis and Rheumatism*. 44:S298 (Abstract 973).
173. *S.W. Martin, L. Nguyen, B.J. Stouch, J. Frazier, G. Jayne, N.P. Lam, J.R. Caldwell, H. Offenber, D. Furst, M.W. Davis, **C.K. Edwards, III**, and B.B. Yang. The pharmacokinetics (PK) of Anakinra (Interleukin-1 receptor antagonist, IL-1ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) do not alter combination treatment in subjects with rheumatoid arthritis (RA). Presented at the 65th Annual Scientific Meeting of the American College of Rheumatology. San Francisco, CA, November 11-16, 2001. *Arthritis and Rheumatism*. 44:S298 (Abstract 159).
174. *E. Brahn, D. Fitzpatrick, A. Williams, M.L. Banquerigo, K. Kalunian, M.J. Gresser, and **C.K. Edwards, III**. Rheumatoid arthritis synovium: cluster analysis and microarray mRNA expression profiles using 23,614 gene elements. Presented at the 65th Annual Scientific Meeting of the American College of Rheumatology. San Francisco, CA, November 11-16, 2001. *Arthritis and Rheumatism*. 44:S298 (Abstract 2072).
175. *E. Brahn, D. Fitzpatrick, A. Williams, S. Lee, N. R. Schoettler, M.L. Banquerigo, D. Khanna, B. Liu, M.J. Gresser, and **C.K. Edwards, III**. Microarray expression profiles of collagen-induced arthritis using 4000 gene elements: Studies with sTNF-RI and IL-1ra as single and combination therapy. Presented at the 65th Annual Scientific Meeting of the American College of Rheumatology. San Francisco, CA, November 11-16, 2001. *Arthritis and Rheumatism*. 44:S298 (Abstract 1137).

176. *J.R. Caldwell, H. Offenberg, D. Furst, N.P. Lam, T. Joh, M.W. Davis, and **C.K. Edwards, III**. A phase I safety study of combination treatment with PEGylated soluble tumor necrosis factor receptor I (PEG sTNF-RI) and Anakinra (Interleukin-1 Receptor Antagonist; IL-1ra) in subjects with rheumatoid arthritis. *Presented at* the 65th Annual Scientific Meeting of the American College of Rheumatology. San Francisco, CA, November 11-16, 2001. *Arthritis and Rheumatism*. 44:S298 (Abstract 1904).
177. *J.R. Caldwell, H. Offenberg, D. Furst, N.P. Lam, G. Jayne, T. Joh, M. Davis, and **C.K. Edwards, III**. 2002. A phase I safety study of combination treatment with PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and Anakinra (interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. *Presented at* the Annual European Congress of Rheumatology. Stockholm, Sweden, June 12-15, 2002.
178. *S.W. Martin, L. Nguyen, B.J. Stouch, J. Frazier, G. Jayne, N.P. Lam, J.R. Caldwell, H. Offenberg, D. Furst, M.W. Davis, **C.K. Edwards, III**, B. Yang. 2002. Pharmacokinetics (PK) of anakinra and PEGylated soluble tumor necrosis factor receptor type I (Pegsuncept) were not altered after combination treatment in subjects with rheumatoid arthritis (RA). *Presented at* the Annual European Congress of Rheumatology. Stockholm, Sweden, June 12-15, 2002.
179. ***C.K. Edwards, III**, R. Baltera, D. Miller, M. Gresser, S. Dinarello, V. Marsh, K.A. Storm, D. M. Bankaitis-Davis, and M.P. Bevilacqua. 2002. Select inhibition of IL-1 β -induced proinflammatory gene expression by recombinant IL-1 receptor antagonist (IL-1ra; Anakinra) in human whole blood cultures: contrast to other anti-inflammatory agents. *Presented at* the Annual European Congress of Rheumatology. Stockholm, Sweden, June 12-15, 2002.
180. *S.P. Mallard, S.W. Martin, J.L. Frazier, S. Baughman, J.D. Young, A.M. Solinger, and **C.K. Edwards, III**. 2002. Interspecies pharmacokinetic comparisons and allometric scaling of PEG sTNFbp dumbbell, a 20 kDa PEG linker bound both ends to tumor necrosis factor receptor type I receptor. *Presented at* the Annual meeting of the American Association of Pharmaceutical Science. San Diego, CA. June 23-26, 2002 (Poster #3033).
181. *M. Stenkilsson, S. Mallard, J. Frazier, S. Baughman, J. Young, A. Solinger, L.L. Moldawer, **C.K. Edwards, III**, S.W. Martin. 2002. Interspecies pharmacokinetic comparisons and allometric scaling of PEG sTNF-RI, a 30-kDa PEGylated low molecular weight (14 kDa) protein. *Presented at* the Annual meeting of the American Association of Pharmaceutical Science. San Diego, CA. June 23-26, 2002 (Poster #3032).
182. *S.W. Martin, R.A. Harrell, J.L. Frazier, A.M. Solinger, S. Baughman, J. Young, and **C.K. Edwards, III**. 2002. Use of sparse sampling and SAS proc mixed effects model to quantify drug exposure (AUC) of PEG sTNF-RI in amniotic fluid, fetal and maternal plasma of rats. *Presented at* the Annual meeting of the American Association of Pharmaceutical Science. San Diego, CA. June 23-26, 2002.
183. *S.W. Martin, R.A. Harrell, M. Hayashi, H. Kohno, S. Baughman, A.M. Solinger, and **C.K. Edwards, III**. 2002. Quantitative whole body autoradiography and excretion of ¹²⁵I-PEG r-metHu-sTNF-RI in rats. *Presented at* the Annual meeting of the American Association of Pharmaceutical Science. San Diego, CA. June 23-26, 2002 (Poster #3054).
184. *S.W. Martin, R.A. Harrell, M. Hayashi, H. Kohno, S. Baughman, A.M. Solinger, and **C.K. Edwards, III**. 2002. Quantitative whole body autoradiography and excretion of ¹²⁵I-PEG rmetHusTNF-RI in rats. *Presented at* the Annual meeting of the American Association of Pharmaceutical Science. San Diego, CA. June 23-26, 2002 (Poster #33044).
185. *E.M. Cantin, P. Lundberg, H. Openshaw, **C.K. Edwards, III**, L. Moldawer, and K. Weinberg. 2002. A genetic determinant of resistance to HSV. *Presented at* the International Herpes virus Workshop, Cairns, Australia, July 20-26, 2002.
186. *T. Rooney, P. Roux-Lombard, J-M. Dayer, O. Fitzgerald, D.J. Veale, N. Wright, E. Lawrence, Dennis Miller, **C.K. Edwards, III**, and B. Bresnihan. 2002. Combination therapy with Anakinra (r-metHuIL-1ra) and PEGylated soluble tumor necrosis factor type I (PEG sTNF-RI) in rheumatoid arthritis: a study of serum proinflammatory cytokines and their inhibitors. *Presented at* the Annual Meeting of The American College of Rheumatology. New Orleans, LA, October 25-29, 2002.
187. *T. Rooney, A. Williams, J-M. Dayer, O. Fitzgerald, D. Veale, E. Murphy, **C.K. Edwards, III**, and B. Bresnihan. 2002. Combination therapy with Interleukin-1 receptor antagonist (IL-1Ra) and PEGylated

- soluble tumor necrosis factor receptor type I (PEG sTNF-RI) in rheumatoid arthritis (RA): a study of early clinical and synovial tissue responses. *Presented at* the Annual Meeting of The American College of Rheumatology. New Orleans, LA, October 25-29, 2002.
188. ***C.K. Edwards, III**, A. Williams, V.D. Fitzpatrick, T. Rooney, O. Fitzgerald, D. Veale, E. Murphy, N. Wright, E. Lawrence, D. Miller, J-M. Dayer and B. Bresnihan. 2002. Combination therapy with Anakinra (r-metHuIL-1ra) and PEGylated Soluble Tumor Necrosis Factor Receptor Type I (PEG sTNF-RI) in Rheumatoid Arthritis (RA): Cluster analysis and microarray mRNA expression profiles of patient synovium and peripheral blood. *Presented at* the Annual Meeting of The American College of Rheumatology. New Orleans, LA, October 25-29, 2002.
 189. *T. Rooney, D. Bankaitis-Davis, D. Trollinger, O. Fitzgerald, D. Veale, E. Murphy, N. Wright, E. Lawrence, D. Miller, J-M Dayer, B. Bresnihan, and **C.K. Edwards, III**. 2002. Combination therapy with Anakinra (r-metHuIL-1ra) and PEGylated Soluble Tumor Necrosis Factor Receptor Type I (PEG sTNF-RI) in Rheumatoid Arthritis (RA): Quantitative PCR analysis of inflammatory gene expression in whole blood. *Presented at* the Annual Meeting of The American College of Rheumatology. New Orleans, LA, October 25-29, 2002.
 190. *M. Zhang, K. Gaida, N. Shen Chow, A.A. Welcher, Q. Liu, B. Liu, M. Damore, V.D. Fitzpatrick, **C.K. Edwards, III**. 2002. Functional characterization of human CD4⁺CD25⁺ Regulatory T cells. *Presented at* the Annual Meeting of The American College of Rheumatology. New Orleans, LA, October 25-29, 2002.
 191. *K. Liu, B. Liu, K. Gaida, M. Zhang, M. Stolina, J. Carnihan, H. Kohno, D. Burger, J-M Dayer, and **C.K. Edwards, III**. 2002. Cell-cell contact with activated human T cells induces monocyte IL-1 β and TNF- α production: Surface Activating Factors of T cells (SAFTs) as potential therapeutic targets. *Presented at* the 9th International Congress on TNF-Related Cytokines. TNF Superfamily Conference 2002. San Diego, CA, October 20-24, 2002.
 192. Liu, B., K. Liu, M. Zhang, K. Gaida, C. Piddington, D. Fitzpatrick, R. Luethy, M. Dalphin, M. Boedigheimer, M. Bass, and ***C.K. Edwards, III**. 2003. The hunt for surface activating factors of human T cells (SAFTs): the microarray approach. *Presented at* Keystone Symposia: Mechanisms of Immunologic Tolerance and its Breakdown. *Keystone Symposia Abstracts*. Keystone, CO. January 7-13, 2003 (Poster 250). P. 84.
 193. *Zhang, M., D. Fitzpatrick, C. Piddington, M. Boedigheimer, K. Liu, B. Liu, K. Gaida, A. Norment, M. Gresser, and **C.K. Edwards, III**. 2003. Functional characterization and gene expression analysis of human CD4⁺CD25⁺ regulatory T cell lines. *Presented at* Keystone Symposia: Mechanisms of Immunologic Tolerance and its Breakdown. *Keystone Symposia Abstracts*. Keystone, CO. January 7-13, 2003 (Poster 255). P. 85.
 194. *Wang, X., H-C Hsu, A. Tousson, Y.-Y Y. Li, P. Yang, Q. Wu, **C.K. Edwards, III**, and J.D. Mountz. 2004. Evaluation of T-cell migration by *in vivo* imaging using the oxazolone induced contact hypersensitivity model. *Presented at* The American Association of Immunologists Annual Meeting, Washington, D.C. April 17-21, 2004. *FASEB Journal*.
 195. ***Edwards, III, C.K.**, G.R. Burmeister, H.-D. Volk, M. Schiff, B.L. Kotzin, H. Mitsuya, K.-M. Sakata, J. Cheronis, V. Tryon, D. Trollinger, D. Bankaitis-Davis, K. Storm, Y.Y.Y Li, C.A. Dinarello, D.A. Norris, and M.P. Bevilacqua. 2005. Anti-TNF α therapy in a defined subpopulation of rheumatoid arthritis patients reduces inflammatory gene expression in whole blood in comparison to standard DMARD therapy alone. *Presented at the* American College of Rheumatology Annual Conference, November 13-17, 2005, San Diego, CA. *Arthritis and Rheumatism* 2005. 52: S417 (Abstract #1079).
 196. ***Edwards, III, C.K.**, E. Callaway, B. Liu, Y-Y. Y Li, C.A. Dinarello, M. Fujita, M.J. Gresser, and D.A. Norris. 2005. Novel surface activating factors of human T cells (SAFTs), including CD40 ligand, obtained from psoriatic arthritis and psoriasis patients, augment T cell driven macrophage activation to produce proinflammatory cytokines. *Presented at the* American College of Rheumatology Annual Conference, November 13-17, 2005, San Diego, CA. *Arthritis and Rheumatism* 2005. 52: S476 (Abstract #1247).
 197. ***Edwards, III, C.K.**, E. Callaway, L.-J. Hu, M. Fujita, C.A. Dinarello, and D.A. Norris. 2005. CD4⁺CD45RO⁺CLA⁺CCR4⁺CCR10⁺ T cells obtained from chronic plaque psoriasis (CPPs) patients

- activate autologous mononuclear cells to secrete elevated TNF α and IL-1 β during cell-cell contact. Presented at the Psoriasis: From Gene to Clinic: 4th International Conference on Psoriasis Pathogenesis, December 1-3, 2005; London, England, U.K.
198. *Li, Y.-Y. Y., M. Bao, J. Meurer, W. Skuballa, J. Bauman, W.-D. Doecke, **C.K. Edwards, III**, and T. M. Zollner. 2006. Human peripheral blood T cell-monocyte cell-cell contact bioassay can be utilized to identify small molecule inhibitors that specifically inhibit T cell-mediated adaptive, but not LPS-mediated innate, immunity. To be presented at: The Society for Investigative Dermatology Annual Meeting, May 3-6, 2006, Philadelphia, PA. *J. Invest. Dermatol.* 126:13 (Abstract 57).
 199. *Hu, L.-J., E.K. Callaway, J.E. Fitzpatrick, M. Fujita, M.K. Takashi, L. Li, K. R. Shroyer, T. K. Azam, S-H. Kim, C.A. Dinarello, D.A. Norris, and **C.K. Edwards, III**. 2006. Interleukin-32 in the pathogenesis of chronic plaque psoriasis. Presented at: The Society for Investigative Dermatology Annual Meeting, May 3-6, 2006, Philadelphia, PA. *J. Invest. Dermatol.* 126:12 (Abstract 72).
 200. *Li, L., E. Callaway, L.J. Hu, M. Fujita, D.A. Norris, and **C.K. Edwards, III**. 2006. Role of TCISM in the pathogenesis of chronic plaque psoriasis. Presented at: The Society for Investigative Dermatology Annual Meeting, May 3-6, 2006, Philadelphia, PA. *J. Invest. Dermatol.* 126:13 (Abstract 73).
 201. *Li, L., E. Callaway, L.-J. Hu, C.A. Dinarello, M. Fujita, J.-M. Dayer, D.A. Norris, and **C.K. Edwards, III**. 2007. Novel human T-cell cytokine inducing surface molecules (TCISMs), including CD40 ligand, augments T cell driven macrophage activation to produce proinflammatory cytokines. Presented at: Montagna Symposium on the Biology of the Skin - Epidermal T cell interactions: Clinicopathologic and Basic Mechanisms. October 11 -15, 2007, Gleneden Beach, OR.
 202. *Jonscher, K.R., L. Li, B. Schneidewind, L.-J. Hu, D.A. Norris and **C.K. Edwards, III**. 2007. Toward the identification of proteins in activated human T cells that drive macrophage activation and proinflammatory cytokine production. Presented at: Montagna Symposium on the Biology of the Skin - Epidermal T cell interactions: Clinicopathologic and Basic Mechanisms. October 11 -15, 2007, Gleneden Beach, OR.
 203. ***Edwards, III, C.K.**, L.-J. Hu, L. Li, J.E. Fitzpatrick, S.O. Francis, K.R. Jonscher, M. Zhu, M. Fujita, M. K. Takashi, K.R. Shroyer, T. K. Azam, S-H. Kim, C.A. Dinarello and D.A. Norris. 2007. The proinflammatory cytokine interleukin 32 γ is expressed in keratinocytes and dendritic cells obtained from patients with chronic plaque psoriasis. Presented at: Montagna Symposium on the Biology of the Skin - Epidermal T cell interactions: Clinicopathologic and Basic Mechanisms. October 11 -15, 2007, Gleneden Beach, OR.
 204. *Francis, S.O., L. Li, M. Fujita, D.A. Norris, C.A. Dinarello and **C.K. Edwards, III**. 2007. The T-cell targeted molecules efalizumab and alefacept do not block T-cell mediated activation of macrophages for increased TNF α , IL1 β , and IL32 γ production., Presented at: Montagna Symposium on the Biology of the Skin - Epidermal T cell interactions: Clinicopathologic and Basic Mechanisms. October 11 -15, 2007, Gleneden Beach, OR.
 205. *Jonscher, K.R., Li, L., Eisenmesser, E.Z., Norris, D.A., **Edwards, III, C.K.** 2009. Identification of a novel pathway in stimulated human T cells that drives macrophage activation and cytokine production. Presented at: The Association of Biomolecular Resource Facilities Annual Meeting. Feb. 7-10, 2009, Memphis, TN.
 206. *Francis, S.O., Fujita, M., Dellavalle, R., Norris, D.A., **Edwards, III, C.K.** 2009. Gene expression/qRT-PCR analysis in psoriatic disease: Translational approaches to identify responder from non-responder psoriasis patients treated with anti-TNF α biologics. Presented at: Annual Meeting of The Society of Investigational Dermatology, Montreal Quebec May 6-9, 2009.
 207. Francis, S.O., Hu, L.-J., *Asokan, R., Fujita, M., Kim, S.-H., Dinarello, C.A., Norris, D.A., **Edwards, III, C.K.** 2009. CD4⁺CD45RO⁺CCR4⁺ memory T cells activate keratinocytes to produce the proinflammatory cytokine IL32 γ in a cell-cell contact manner: Implications for the pathogenesis of psoriasis. Presented at: Annual Meeting of The Society of Investigational Dermatology, Montreal Quebec May 6-9, 2009.
 208. *Jonscher, K.R., Li, L., Eisenmesser, E.Z., Fujita, M., Norris, D.A., **Edwards, III, C.K.** 2009. Determining the roles of FKBP52 and CD147: EMMPRIN to stimulated human T cells leading to

macrophage activation and proinflammatory cytokine production. *Presented at:* Annual Meeting of The Society of Investigational Dermatology, Montreal Quebec May 6-9, 2009.

209. ***Edwards, III, C.K.**, Rengasamy, A, Jonscher, K., Li, L., Eisenmesser, E.Z., Fujita, M., Norris, D.A. 2009. Utilization of translational “bench-to bedside” clinical protocols to elucidate the roles of cyclophilins in mediating human T cell-mediated macrophage activation: Drug discovery approaches to identify novel therapeutic targets mediating adaptive immunity but leaving innate immunity intact. *Presented at:* BIT 7th Annual Congress of International Drug Discovery Science and Technology (IDDST), Shanghai, China, October 22-25, 2009.
210. Yang J., Xiong, L., Jin, W., Akana, H., Redzic, J., Eisenmesser, E.Z., Klein, M.L., Edwards, III, C.K. 2010. The novel proinflammatory cytokine interleukin-39 (IL39) stimulates PMA or MCSF-1 differentiated human macrophages (M ϕ) to produce TNF α , IL1 β , and IL32 γ . *Presented at:* BIT 8th Annual Congress of International Drug Discovery Science and Technology (IDDST), Section 8-2”: Translational Medicine and Globalization Strategies, Beijing, China, October 23, 2010.

E. Commercial Publications:

1. Zhang, J. and **C.K. Edwards, III.** 1991. Neuroendocrinimmunology of Aging and Autoimmune Disease. *In* K. Sorensen (Ed.) *Inside Science*. Marion Merrell Dow Publication Press. Kansas City, MO. 1:27-36.
2. **Edwards, III, C.K.** and D.R. Borcharding. 1993. Specific inhibition of tumor necrosis factor- α by novel carbocyclic nucleosides: Therapeutic implications for systemic inflammatory response syndrome (SIRS). *In* C. Jarrell (Ed.) *Inside Science*. Marion Merrell Dow Publication Press. Kansas City, MO. 3:14-22.
3. **Edwards, III, CK.** 1999. sTNF-RI Completes Successful Phase 1 Clinical Trial. *Amgems*. Amgen Press. April/May/June 1999.

F. Patents (selected from a list of 50):

1. Methods for Controlling Helminthic Parasites. *US Patent* 4,778, 821. 1986.
2. Immunostimulating Agents. *European Patent* 251,813. 1987.
3. Peptide FK565 as an Anthelmintic. *European Patent* 305,174. 1987.
4. Immunostimulating Agents. *US Patent* 4,842,862. 1987.
5. Method for Enhancing Disease Resistance Using Somatotropin. *US Patent* 4,321,940. 1989.
6. Method for Enhancing Disease Resistance Using Somatotropin Incorporated into Liposomes. Pitman-Moore, Inc. Patent Filing Case 3164 (1991).
7. Method for Stimulating the Immune System. *US Patent* 4,837,202. 1990.
8. Method for Stimulating the Immune System. *US Patent* 5,028,591. 1991.
9. Novel Carbocyclic Adenosine Analogs as Immunosuppressant's. Marion Merrell Dow, Inc. *US Patent* 5,244,896. 1993.
10. Carbocyclic adenosine analogs useful as Immunosuppressant's. Marion Merrell Dow, Inc. *US Patent* 5,470, 857. November 28, 1995.
11. Carbocyclic Adenosine Analogs as Immunosuppressant's. Marion Merrell Dow, Inc. *U.S. Patent* 5,514,688. May 7, 1996.
12. 6-Oxo-Nucleosides Useful as Immunosuppressant's. Marion Merrell Dow, Inc. *European Patent* 95900365.8-2101. October 25, 1996.
13. Method of effecting immunosuppression by administering carbocyclic adenosine analogs. Marion Merrell Dow, Inc., *U.S. Patent* 5,631, 258. May 20, 1997.
14. Novel Trans Cyclopental Adenosine Analogs Useful as Immunosuppressant's. Marion Merrell Dow, Inc. *U.S. Patent* 5,817,660. October 6, 1998.
15. Trans Cyclopentanyl Deazaadenyl Analogs useful as Immunosuppressant's. Marion Merrell Dow, Inc. *U.S. Patent* 5,905,085. , May 18, 1999
16. Trans Cyclopentanyl Deazaadenyl Analogs useful as Immunosuppressant's. Marion Merrell Dow, Inc. *U.S. Patent* 5,916,892. June 29, 1999
17. Trans Cyclopentanyl Azaadenyl Analogs useful as Immunosuppressant's. Marion Merrell Dow, Inc. *U.S.*

- Patent 5,929,079. July 27, 1999*
18. Trans Cyclopentanyl Purine Analogs useful as Immunosuppressant's. Aventis Corporation. *U.S. Patent 6,436,947. August 20, 2002.*
 19. Novel Bicyclic Carbocyclic Adenosine Agents Useful as Inhibitors of Proinflammatory Cytokines. Marion Merrell Dow, Inc. *U.S. Patent 6,541, 482 B2. April 1, 2003.*
 20. New Truncated Soluble TNF receptor molecules - useful for treating e.g. arthritis, chronic inflammatory disease, ARDS, cachexia, anorexia, and cancer. Forms of Tumor Necrosis Factor Binding Protein. Amgen, Inc. *Patent Filing PCT WO980155-A2 (January 15, 1998).*
 21. Apolipoprotein AI Regulation of T-cell Signaling. Amgen, Inc. *WHO Patent Filing March 15, 2001.*
 22. T-cell targeted bispecific antibodies to treat psoriasis and immune disease. Berlex Biosciences/Schering AG. *WHO Patent Filing April 15, 2004.*
 23. T-cell cytokine-inducing surface molecules and methods of use. International Publication Number WO2008/151307 A2, December 11, 2008.
 24. *Dual Inhibition of Immunophilin/Cyclophilin and Emmpirin Immunoglobulin Receptor Superfamily Members, Patent #2010/091324 A1, issued 2010.*

References Furnished upon Request